

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

In clinical and community-based samples, do insomnia and/or sleep disturbances compared to typical sleep predict child and youth depression? Protocol for a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034606
Article Type:	Protocol
Date Submitted by the Author:	27-Sep-2019
Complete List of Authors:	marino, cecilia; Centre for Addiction and Mental Health, Andrade, Brendan; University of Toronto Department of Psychiatry, Aitken, Madison; Centre for Addiction and Mental Health Bonato, Sarah; Centre for Addiction and Mental Health Centre for Addiction and Mental Health, Library Services Haltigan, John; Centre for Addiction and Mental Health Wang, Wei; Centre for Addiction and Mental Health Szatmari, Peter; Centre for Addiction and Mental Health
Keywords:	SLEEP MEDICINE, Depression & mood disorders < PSYCHIATRY, Child & adolescent psychiatry < PSYCHIATRY, longitudinal studies, systematic review

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **In clinical and community-based samples, do insomnia and/or sleep disturbances compared to**
4 **typical sleep predict child and youth depression? Protocol for a systematic review and meta-**
5 **analysis**
6
7
8
9

10 Cecilia Marino^{1,2}, Brendan Andrade^{1,2}, Madison Aitken,^{1,2} Sarah Bonato¹, John Haltigan^{1,2}, Wei Wang^{1,2} and
11 Peter Szatmari^{1,2,3}
12

13
14 ¹ Cundill Centre for Child and Youth Depression, Center for Addiction and Mental Health, Toronto, Canada

15
16 ² Department of Psychiatry, University of Toronto, Toronto, Canada

17
18 ³ Hospital for Sick Children, Toronto, Ontario, Canada

19
20 Corresponding author: Cecilia Marino, Centre for Addiction and Mental Health (CAMH), 80 Workman Way,
21 Room 1236, Toronto, ON M6J 1H4, e-mail: cecilia.marino@utoronto.ca, Tel: 416-535-8501 Ext. 35134
22

23
24 Brendan Andrade, Brendan.Andrade@camh.ca

25
26 Madison Aitken, Madison.Aitken@camh.ca

27
28 Sarah Bonato, Sarah.Bonato@camh.ca

29
30 John Haltigan, John.Haltigan@camh.ca

31
32 Wei Wang, Wei.Wang@camh.ca

33
34 Peter Szatmari, peter.szatmari@utoronto.ca
35
36
37
38
39
40

41 **Abstract**

42
43 **Introduction**

44
45 Disturbed sleep represents a potentially important modifiable risk factor for the development of depression
46 in children and youth. This protocol for a systematic review proposes to investigate whether insomnia
47 and/or sleep disturbances predict child and youth depression in community and clinical-based samples.
48
49

50
51 **Methods and analysis**

52
53 The protocol adheres to the Preferred Reporting Items for Systematic Review and Meta-Analysis protocols
54 (PRISMA-P) guidelines. English-written, prospective, longitudinal observational studies that quantitatively
55 estimated the prediction of depression by insomnia and/or sleep disturbances in individuals 5-24 years of
56 age will be included. EMBASE, MEDLINE, PsychINFO, Scopus and Web of Science and grey literature will
57 be searched from 1980 to the present. For the selection of studies, two reviewers will be involved. Data
58
59
60

1
2
3 extraction will be conducted by one author and checked independently by a second author using a pre-
4 defined data extraction form. Risk of bias will be appraised using the Research Triangle Institute Item Bank
5 (RTI-IB) tool. Heterogeneity will be measured using the I^2 statistic. Meta-analysis will be carried out if $I^2 \leq$
6
7 75% and if ≥ 3 results are available and if outcome measures can be pooled. The random-effect model will
8
9 be used if $I^2 \geq 50$ is detected, otherwise the fixed-effect model. Results of the meta-analyses will be
10
11 summarized by a forest plot. Analyses will be performed in subgroups stratified by key variables, e.g. risk of
12
13 bias score, type of ascertainment, type of sleep disturbance, measurement of outcome, presence of
14
15 baseline comorbidity, sample size, age group, gender. Subgroups will be defined depending on the amount
16
17 and type of information retrieved.

18
19
20 A narrative synthesis will be conducted in place of the meta-analysis, should pooling of data not be
21
22 possible. Quality of evidence will be rated using the Grading of Recommendations Assessment,
23
24 Development, and Evaluation (GRADE) guidelines.

25 26 27 28 **Strengths and limitations of this study**

- 29
30 • This is a protocol for a systematic review and meta-analysis of existing prospective, longitudinal
31
32 evidence on insomnia and/or sleep disturbances predicting depression in children and youth.
- 33
34 • This protocol will adhere to the Preferred Reporting Items for Systematic review and Meta-Analysis
35
36 protocols (PRISMA-P) guidelines
- 37
38 • This protocol is registered at PROSPERO, the international prospective register of systematic
39
40 reviews
- 41
42 • Full-text screening and extraction will be performed by two reviewers. Any uncertainty regarding
43
44 selection will be resolved by consensus and if necessary, by a third reviewer.
- 45
46 • With regards to limitations, the review will not include treatment studies and will include only
47
48 English-written articles. We include individuals aged 5-24 years, therefore excluding studies on
49
50 child and youth disturbed sleep predicting depression at later stages of life.

51
52
53
54
55 **Ethics and dissemination** As this is a protocol for systematic review and meta-analysis of published data,
56
57 ethics review and approval are not required. The findings will be published in a peer-reviewed journal and
58
59 disseminated at scientific conferences and to patient advocacy organizations.

1
2
3 **Trial registration number: International Prospective Register for Systematic Reviews (PROSPERO)**
4 **registration number CRD42019136729.**
5
6
7
8
9

10 **Introduction**

11
12 Depression affects 2-4% of children and 11% of youth between 13 and 18 years of age, and peaks at 20
13 years of age¹ with disrupting effects on normative developmental trajectories. Prevalence is equal for both
14 sexes prior to puberty, then it is higher in females.² Treatment shows limited efficacy,³⁻⁵ suggesting that
15 prevention may be a more effective resource to reduce the incidence of depression.
16
17

18 Targeting modifiable risk factors of illnesses is becoming a relevant therapeutic strategy for disease
19 prevention.⁶ Among modifiable risk factors predicting child and youth depression, insomnia is increasingly
20 recognized as an important component of the complex and multi-factorial causal pathway of depression.⁷
21 Treating insomnia to specifically reduce the incidence and/or severity of depression has been the focus of
22 controlled, high quality, randomized treatment studies in depressed or at risk for depression adult or elderly
23 individuals.^{8,9} In a recent meta-analysis, internet-based cognitive behavioural therapy (CBT) for insomnia
24 had a significant, small effect on comorbid depression in individuals older than 18 years.¹⁰
25
26

27 Similar evidence in younger individuals is scarce, mostly consists of studies with small sample size/no
28 follow-up, and it is limited to individuals older than 12 years of age¹¹⁻¹⁷.
29
30

31 In a randomized controlled trial, CBT for insomnia for six weekly sessions and a booster session after 2
32 months was significantly more effective in decreasing comorbid depression compared to waitlist in 12-19-
33 year-old individuals with DSM-5 insomnia and no comorbid psychiatric disorders. The effect was large, was
34 maintained after 12 months, and was fully mediated by the reduction of insomnia symptoms.¹⁶
35
36

37 In a longitudinal, randomised controlled trial study (SENSE, i.e. Sleep and Education: learning New Skills
38 Early) the preventative effect on the incidence of depression in at risk for depression, 12-17-year-old
39 adolescents with sleeping difficulties is investigated.¹² The interventions consist of seven weekly sessions of
40 either a CBT/mindfulness-based sleep intervention or an active control intervention, followed by two booster
41 sessions after three and six months post-intervention. One-hundred-twenty-three participants have
42 completed the interventions,^{13,14} however findings regarding the main outcomes of the study (preventative
43 effects of depression) from the two-year follow-up are not available yet.
44
45

46 It is currently not known whether treating sleep problems in affected or unaffected, at risk for depression
47 children (e.g. children with history of abuse, with high emotional dysregulation, offspring of depressed
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 parents) would lead to a lower incidence of depression than it would be if sleep problems were not
4 treated.¹⁸ To understand whether earlier prevention efforts could be more effective, a precise quantitative
5 estimate of the prediction of depression by insomnia in the entire developmental population, including
6 clinical and non-clinical individuals, is needed.
7
8
9

10 Insomnia consists of clinically significant long sleep-onset latency and/or awakening after sleep onset
11 and/or early-morning awakening, accompanied by diurnal tiredness and functional impairment. Prevalence
12 of insomnia is 19.5% in children, equally distributed among boys and girls; in youth, prevalence is 17.4%,
13 and higher among girls.¹⁹
14
15
16
17

18 Six systematic reviews have summarized cohort studies on insomnia predicting depression.²⁰⁻²⁵ Estimates
19 of the meta-analytic odds ratios are consistent across studies ranging 2.10-2.83,^{21 24} and across subgroups
20 stratified by the most common confounders, e.g. sex (male: 1.46; females: 1.96), type of ascertainment
21 (clinical: 2.05; non-clinical: 2.34), and age (elderly 1.87-1.92; adults: 2.50).²³
22
23
24
25

26 However, only three of the six systematic reviews included subjects younger than 18 years,^{21 22} and a meta-
27 analytic estimate, i.e. odds ratio= 2.0, was provided by only one of the three reviews.²¹ This estimate was
28 based on studies up to 2010, and included only three studies.²⁶⁻²⁸ Li et al. updated and used the same
29 selection criteria of Baglioni et al.²¹ and although fifteen new cohort studies were added, no new studies on
30 children and youth were included. Finally, Pigeon et al.²² summarized studies published from 2014 to 2017;
31 four studies on children and youth were included, of which three supported insomnia predicting
32 depression,²⁹⁻³¹ and one found no such association.³² In sum, while it is well established that insomnia is a
33 risk factor for depression in adults and the elderly,²⁰⁻²⁴ an updated systematic review and meta-analysis on
34 whether insomnia predicts child and youth depression is missing. The most recent review for children and
35 youth is based on studies up to 2010 and all three systematic reviews of this age group excluded studies
36 which did not control for baseline depression. This led to a greatly reduced number of studies. While the
37 rationale of this choice is clear for studies of risk and prediction, it might not have been the ideal choice,
38 due to the overall paucity of studies in the child and youth age-range compared to other age groups.
39
40
41
42
43
44
45
46
47
48
49

50 Including studies that did not control for baseline depression would allow testing of whether there are
51 significant differences in the meta-analytic estimates between studies controlling versus not-controlling for
52 this variable. If no differences are found, studies not controlling for baseline depression could contribute to
53 the pooled data with an overall increase of the precision for the estimate of the meta-analytic effects.
54
55
56
57

58 There is also some evidence available on whether sleep disturbances other than insomnia predicts child
59 and youth depression.³³⁻⁴² This may include increased/short/disrupted sleep duration with/without diurnal
60

1
2
3 sleepiness, sleepwalking/talking, nightmares, bedwetting, breathing-related sleep disorders, and/or
4 circadian disturbances. Furthermore, sleep disturbances more broadly defined may include challenges
5 either generically defined with regards to duration and consistency over time, measured by self-reported
6 questionnaires, interview or by EEG/actigraph-based measures, and scored by either single-item or
7 cumulative scores. A recent meta-analysis summarized studies testing the association of broadly defined
8 sleep disturbances on depression in 12-20-year-old already clinically depressed subjects. In all selected
9 studies,⁴³⁻⁴⁹ sleep was defined by EEG-based, objective measures. Estimates of the meta-analytic effects
10 identified that EEG-based longer sleep onset latency, more wake after sleep onset and lower sleep efficiency
11 were significant predictors of depression compared to typical sleep (effect sizes ranging .43-.58).⁵⁰
12 Although findings from this review are of crucial importance for potential secondary prevention programs in
13 depressed youth, it would be useful to have summarized data on the longitudinal association of broadly
14 defined sleep disturbances with depression on the entire developmental population, including non-clinical
15 individuals as well as a broader age range, which would allow to apply findings to primary prevention and/or
16 early intervention programs.

17
18
19
20
21
22
23
24
25
26
27
28
29
30 Finally, insomnia and/or sleep disturbances are often associated to comorbid psychiatric and medical
31 conditions.¹⁸ Most previous knowledge synthesis studies have excluded comorbidities, limiting the
32 generalizability and transferability of findings. For this reason, in this systematic review studies focusing on
33 both primary and comorbid insomnia and/or sleep disturbances will be included. To understand the extent
34 to which insomnia and/or sleep disturbances have a distinct risk to depression across comorbid disorders,
35 subgroup analyses will be performed.

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52 Understanding whether insomnia and/or sleep disturbances significantly increase the risk of depression in
53 children and youth could lead to variation in clinical practice and inform policy development. Preventive
54 strategies could include treating sleep problems starting as early as childhood. This is particularly important
55 in light of evidence on the differential effectiveness of a number of treatment for sleep problems (e.g.
56 melatonin,^{51 52} cognitive behavioural therapy,⁵³ physical exercise,⁵⁴ and bright light therapy⁵⁵) and the fact
57 that sleep problems in children are under-diagnosed⁵⁶ and rarely treated.⁵⁷

58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

The purpose of this protocol is to outline a methods for a systematic review and meta-analysis of data from prospective, longitudinal studies in clinical and community-based samples of children and youth investigating the role of insomnia and/or sleep disturbances compared to typical sleep as predictors of depression. “Do children and youth with insomnia and/or sleep disturbance have higher rates of later depression than children and youth without insomnia and/or sleep disturbance”?

Our study will add to the currently available knowledge synthesis in that:

1. It will provide an updated meta-analytic estimate of the effects of insomnia predicting child and youth depression, adding studies from 2010 onward compared to Baglioni et al.²¹
2. By including studies on 5-24-year-old subjects from both clinical and non-clinical populations, it will provide a more comprehensive and updated meta-analytic estimate compared to Lovato and Gradisar⁵⁰
3. It will include studies whether controlling for baseline depression or not
4. It will include studies of both primary and comorbid insomnia and/or sleep disturbances

Furthermore, we aim to explore the sources of potential heterogeneity and examine the robustness of the primary hypothesis against key confounding variables. Specifically, our secondary aim is to address whether the prediction of child and youth depression by insomnia and/or sleep disturbances significantly differ between studies controlling versus not controlling for baseline depression, and more generally between studies stratified by key variables, e.g. risk of bias score, type of ascertainment, type of sleep disturbance, measurement of outcome, presence of baseline comorbidity, sample size, age group, gender. Subgroups will be defined depending on the amount and type of information retrieved.

Methods

For the protocol, we will follow the guidelines outlined in "Preferred Reporting Items for Systematic review and Meta-Analysis protocols (PRISMA-P)".⁵⁸ For the final report we will follow the guidelines set in "Meta-analysis Of Observational Studies in Epidemiology: a proposal for reporting" (MOOSE).⁵⁹

Inclusion criteria

Study types

This study will include (1) English-written, (2) prospective, longitudinal observational studies that quantitatively estimated the prediction of depression by insomnia and/or sleep disturbances in children and youth. Only those studies reporting descriptive statistics, analyses of trajectories, effect sizes, odds ratios, β scores, frequency, hazard or relative risk will be selected. Grey literature including relevant dissertations/PhD theses and key conference publications will be included. Case series, case reports, systematic reviews, meta-analyses, as well as experimental, retrospective, cross-sectional, treatment, theoretical and position studies will be excluded.

Population type

Studies focusing on subjects aged 5-24 years belonging to either community or clinical based samples with any comorbid psychiatric/neurological/medical diagnosis will be included.

Exposure

Studies will be included if focusing on either one of the following two exposures:

1. Insomnia, defined as clinically significant difficulty in initiating or maintaining sleep or non-restorative sleep, as based on DSM III and later versions. Although the criterion of daytime impairment is required to define clinically significant insomnia, it has been shown that the meta-analytic odds ratio of insomnia predicting depression when this criterion is taken into account²⁴ is of comparable magnitude relative to the ones obtained when this criterion is not considered (Baglioni et al. 2011; Li et al. 2016).²¹ Therefore, to allow for inclusion of the highest number of studies, daytime impairment will be free to vary.
2. Sleep disturbances, defined as increased/short/disrupted sleep duration with or without daytime fatigue/sleepiness, nightmares/terror attacks, circadian disturbances, and/or night walking/talking. Sleep disturbances can be generically defined with regards to duration and consistency over time, and can be based on subjective and/or EEG/actigraph-based, objective measures. Measures can be based on single or multiple items, or a cumulative score of various items. Narcolepsy, breathing-related sleep disorders, central sleep apnea, non-rapid/rapid eye movement sleep disorder, restless legs syndrome, substance/medication-induced sleep disorder, and enuresis nocturna primaria may also be included.

Exposures' assessment can be administered by a clinician, a researcher, or based on self-report, parent-report, and/or teacher-report questionnaires.

Outcome

Studies will be included if they focus on either one of the following outcomes: major depressive disorder, depressive disorder not otherwise specified, dysthymic disorder, and/or dimensional construct of depression, internalizing disorders or anxious depression. Studies focusing on anxiety without a measure of depression will not be included. Outcome is measured by standardized and validated tools administered by a clinician, a researcher, and/or based on self-report, parent-report, and/or teacher-report questionnaires.

1
2
3 To be included, both exposure and outcome have to be measured at mean age ≥ 5 years and ≤ 24 . To
4 address the research question on the role of insomnia and/or sleep disturbances as predictor of depression,
5 only studies reporting on the exposure measured at least one month before the outcome will be included.
6
7 When multiple assessments are conducted on the same cohort, each pair where both exposures and
8
9 outcomes are measured at mean age ≤ 24 and ≥ 5 years and exposures are measured before the outcome
10
11 will be considered.
12
13
14
15

16 **Confounders**

17
18 Studies will be included regardless of whether they contain estimates adjusted for common confounding
19
20 factors, such as sex, socio-economic status, demographics, type of comorbidity at baseline. Studies that do
21
22 not control for common confounding factors will be highlighted for potentially confounded results.
23
24
25

26 **Identification of eligible studies and data extraction**

27 **Search strategy**

28
29 The following databases will be searched: EMBASE, MEDLINE, PsychINFO, Scopus and Web of Science. A
30
31 draft of the Medline search strategy will be developed using a combination of MeSH and keywords terms
32
33 relating to sleep disorders, depression/depressive disorder and children/adolescents/young adults with the
34
35 help of a research librarian. The search will be limited to the years 1980 (to focus on current diagnostic
36
37 terminology from the DSM III) to the present and will also be limited to observational studies using the search
38
39 filter developed by the Scottish Intercollegiate Guidelines Network (SIGN). The draft Medline search will also
40
41 be piloted to ensure the sensitivity and efficacy of the final search strategy and will also be reviewed by all of
42
43 the participating authors. The finalized Medline search will be adapted for each bibliographic database
44
45 individually.
46

47 The grey literature will be screened for relevant material, including use of the search checklist Grey Matters:
48
49 "A Practical Search Tool for Evidence-Based Medicine" from the Canadian Agency for Drugs and
50
51 Technologies in Health (CADTH), and by also searching other sources to identify relevant dissertations/PhD
52
53 theses and conference publications, i.e. Proquest Dissertations and Theses, ProceedingsFirst, PapersFirst,
54
55 Conference Abstracts from Embase, Google Scholar Search. The references of selected articles will also be
56
57 hand-searched for eligible studies and all the searches will be re-run just before the final analyses to identify
58
59 additional relevant studies. Experts in the field will be contacted to locate potentially eligible studies and/or
60
unpublished data.

Selection of studies

Search results will be exported into Covidence, merged and checked for duplicates. For the selection of studies two students will be involved, with minimum an undergraduate level of education in a health-related field and previous experience with the systematic review methodology. They will be given the systematic review protocol and 5-hour training on the content of the systematic review and basic knowledge of the procedure. For the selection of studies based on title&abstract screening, eligible studies will be selected by two reviewers until at least 80% of agreement is achieved with the remainder being selected by one reviewer. For the selection of studies based on full-text screening, reviewers will perform the selection in duplicate. Any uncertainty regarding selection will be resolved by consensus and if necessary, it will be reviewed by a third reviewer. The PRISMA search flow chart will be used to report the number of studies included and excluded at each step in the process, along with the rationale for the exclusion.

Data extraction

Data extraction will be conducted by one author and checked independently by a second author using a pre-defined data extraction form. Extracted variables will pertain to the following domains: general study information, study characteristics, participant characteristics, exposures and outcome measures, interval between baseline and follow-up, sample size, how missing data are handled, covariates that were adjusted in the analyses, outcome data, including effect sizes, odds ratio, relative risk or hazard ratio with respective 95% confidence interval. Information on the sources of funding for each study will be retrieved.

Discrepancies between the two authors will be resolved by discussion. When relevant data are missing, corresponding authors will be contacted to obtain the information.

Risk of bias assessment

Risk of bias of included studies' results will be appraised using the Research Triangle Institute Item Bank (RTI-IB) tool. The RTI-B is a practical, quality-scoring tool for observational studies with a focus on bias and precision.⁶⁰ It has a high inter-rater reliability (75%) and consists of 29 items tapping 12 domains (1) background, (2) sample definition and selection, (3) interventions/exposure, (4) outcomes, (5) creation of treatment groups, (6) blinding, (7) soundness of information, (8) follow-up, (9) analysis comparability, (10) analysis outcome, (11) interpretation, and (12) presentation and reporting. Possible response categories to

1
2
3 each item are 'yes', 'no', 'partially', 'cannot determine', and 'not applicable'. The quality appraisal will be
4 performed by two authors independently with discrepancies being resolved by discussion. Results will be
5 reported narratively and summarized in a descriptive table. Items will be subdivided into six categories:
6 selection bias/confounding, performance bias, attrition bias, detection bias, reporting bias, and information
7 bias. Items are scored as high, low, or unclear risk of bias. If at least one item in a category is scored as
8 high, the risk of bias within this category is scored as moderate risk. If at least 50% of the items in a category
9 are scored as high, the risk of the category is scored as high. Each study will receive a summary score that
10 corresponds to the highest score obtained in any category.⁶⁰

20 **Data synthesis and analysis**

21 Data will be synthesized by a table reporting study type, participant characteristics, exposure and outcome
22 measures, and a second table on the risk of bias assessment. The data will be categorised into each type
23 of exposure, i.e. insomnia and sleep disturbances. Heterogeneity of pooled estimates for each exposure
24 category will be measured using the I^2 statistic, which represents the percentage of variation attributable to
25 between-study heterogeneity. I^2 values of 25%, 50%, and 75% will be considered as low, medium, and high
26 heterogeneity, respectively. Meta-analysis of studies will be carried out if $I^2 \leq 75\%$ and if ≥ 3 results for each
27 exposure category are available.⁶¹ A narrative synthesis will be conducted in place of the meta-analysis,
28 should this latter cannot be performed. For the meta-analysis, the random-effect model will be used if $I^2 \geq$
29 50 is detected, which is robust against both the between-study and within-study variability, otherwise the
30 fixed-effect model will be used. Results of the meta-analyses will be summarized by a forest plot.

31 Meta-analyses will be performed in subgroups stratified by key variables if there are ≥ 3 studies. Such
32 variables include risk of bias score, type of ascertainment, type of sleep disturbance, measurement of
33 outcome, presence of baseline comorbidity, sample size, age group, gender. Subgroups will be defined
34 depending on the amount and type of information retrieved.

35 To assess sensitivity of the pooled estimate to each included study, we will apply the leave-one-out
36 method, which consists of repeating the analysis removing one study at a time.⁶² Potential publication bias
37 and other source of bias will be further assessed by visual inspection of the symmetry of funnel plots.

38 Quality of evidence will be rated using the Grading of Recommendations Assessment, Development, and
39 Evaluation (GRADE) guidelines taking into account risk of bias, applying the RTI-IB tool; heterogeneity;
40 directness, evaluating the relevance of the sample, the outcomes and the exposure; precision, examining
41 the 95% confidence interval; and publication bias of the included studies. We will assess inter-rater

1
2
3 agreement between investigators for study inclusion, data extraction, and methodological quality
4
5 assessment using Kappa Cohen's coefficient.
6
7

8 **Discussion**

9
10 This systematic review and meta-analysis will synthesize and quantify the existing evidence on insomnia
11 and/or sleep disturbances predicting depression in children and youth. While this link is well established
12 and quantified in adult and elderly populations,²⁰⁻²⁴ a comprehensive and updated summary is missing in
13 children and youth.
14
15

16
17 Understanding the magnitude of the risk of sleep problems predicting later depression in children and youth
18 will contribute significantly to the development of treatment and secondary prevention strategies of
19 depression.^{4 5 63} Sleep is often impaired in child and youth depression.⁶⁴ Treating sleep problems in
20 childhood can become an adjunctive tool to treat more effectively childhood depression but also to change
21 the risk trajectories of depression, reducing the incidence and severity of depressive episodes later in life.
22
23

24 This study will also potentially inform strategies for primary prevention of depression in healthy children and
25 youth. Sleep patterns physiologically change from birth to early adulthood as a consequence of a number of
26 maturational changes in the brain, and as a result of an adjustment to the social environment.^{65 66} The most
27 evident change concerns the duration of sleep, which decreases from approximately 14 hours at 6 months
28 of age to 8 hours at 16 years of age.^{67 68} Another relevant maturational change concerns the sleep-onset
29 time, which delays up to approximately 2 hours when transitioning to adolescence. This process is typical of
30 puberty, and it is part of the phase delay of a host of circadian rhythms related to gonadal hormones'
31 changes. The delay in sleep-onset time, called evening chronotype, manifests at a younger age in females
32 than males, corresponding to the sex difference in the onset of puberty.^{66 69} Evidence shows that over the
33 last century child and youth sleep has consistently reduced beyond normative maturational changes.^{70 71} It
34 has been claimed that this "epidemic" shortage of sleep might be related to the concomitant occurrence of
35 the evening chronotype and earlier morning wake-up time of youth compared to younger children.⁷² Other
36 studies claim that decreased sleep in children and youth may instead be due to the increase of electronic
37 screen media use during late hours.⁷³ As a result, an increasing proportion of otherwise healthy children
38 and youth is exposed to insufficient sleep. An open question is whether this newly occurring, sleep-deprived
39 child and youth cohort is at risk of depression. Understanding if the same risk pathway identified in affected
40 or at-risk individuals exists also in typically developing children and youth is essential to understand the size
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and potential consequences of the secular trend toward insufficient sleep and to eventually plan effective
4 programs of primary prevention to reduce the incidence of depression.
5
6
7

8
9 **Ethics and dissemination:** As this is a protocol for systematic review and meta-analysis of published data,
10 ethics review and approval are not required. The findings will be published in a peer-reviewed journal and
11 disseminated at scientific conferences.
12

13
14 **Author contributions:** CM, BA, MA and PS conceived the idea, planned and designed the study protocol.
15 CM wrote the first draft. SB provided expertise to the search strategy. WW provided expertise to the data
16 extraction and statistical analysis. JH provided critical insights. All authors have approved and contributed
17 to the final written manuscript. CM guarantor of the review.
18
19

20
21
22 **Funding statement:** This work was supported by the Cundill Centre for Child and Youth Depression,
23 Centre for Addiction and Mental Health, Toronto, Ontario, Canada. Funder's roles consist of evaluating and
24 funding the grant application if suitable, monitoring and evaluating research outputs, facilitating the
25 implementation of findings in health care, the interaction between researchers and research users, and the
26 dissemination research findings.
27
28

29
30
31 **Competing interests statement.** None declared.
32

33 **Word Count:** 4,130 words.
34

35 Patients or the public WERE NOT involved in the design, or conduct, or reporting, or dissemination of our
36 research
37
38
39
40

41 **References**

- 42
43 1. Avenevoli S, Swendsen J, He JP, et al. Major depression in the national comorbidity survey-adolescent
44 supplement: prevalence, correlates, and treatment. *J Am Acad Child Adolesc Psychiatry*
45 2015;54(1):37-44 e2. doi: 10.1016/j.jaac.2014.10.010 [published Online First: 2014/12/20]
46
47 2. Park RJ, Goodyer IM. Clinical guidelines for depressive disorders in childhood and adolescence. *Eur Child*
48 *Adolesc Psychiatry* 2000;9(3):147-61. [published Online First: 2000/11/30]
49
50 3. Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major
51 depressive disorder in children and adolescents: a network meta-analysis. *Lancet*
52 2016;388(10047):881-90. doi: 10.1016/S0140-6736(16)30385-3 [published Online First: 2016/06/13]
53
54
55
56
57
58
59
60

- 1
2
3 4. Eckshtain D, Kuppens S, Ugueto A, et al. Meta-Analysis: 13-Year Follow-up of Psychotherapy Effects on
4 Youth Depression. *J Am Acad Child Adolesc Psychiatry* 2019 doi: 10.1016/j.jaac.2019.04.002
5
6 [published Online First: 2019/04/21]
7
- 8
9 5. Weisz JR, Kuppens S, Ng MY, et al. Are Psychotherapies for Young People Growing Stronger? Tracking
10 Trends Over Time for Youth Anxiety, Depression, Attention-Deficit/Hyperactivity Disorder, and
11 Conduct Problems. *Perspect Psychol Sci* 2019;14(2):216-37. doi: 10.1177/1745691618805436
12
13 [published Online First: 2018/12/21]
14
15
- 16 6. Gapstur SM, Drope JM, Jacobs EJ, et al. A blueprint for the primary prevention of cancer: Targeting
17 established, modifiable risk factors. *CA Cancer J Clin* 2018;68(6):446-70. doi: 10.3322/caac.21496
18
19 [published Online First: 2018/10/12]
20
21
- 22 7. Cairns KE, Yap MB, Pilkington PD, et al. Risk and protective factors for depression that adolescents can
23 modify: a systematic review and meta-analysis of longitudinal studies. *J Affect Disord* 2014;169:61-
24 75. doi: 10.1016/j.jad.2014.08.006 [published Online First: 2014/08/27]
25
26
27
- 28 8. Christensen H, Batterham PJ, Gosling JA, et al. Effectiveness of an online insomnia program (SHUTi) for
29 prevention of depressive episodes (the GoodNight Study): a randomised controlled trial. *Lancet*
30 *Psychiatry* 2016;3(4):333-41. doi: 10.1016/S2215-0366(15)00536-2 [published Online First:
31
32 2016/02/02]
33
34
- 35 9. Freeman D, Sheaves B, Goodwin GM, et al. The effects of improving sleep on mental health (OASIS): a
36 randomised controlled trial with mediation analysis. *Lancet Psychiatry* 2017;4(10):749-58. doi:
37
38 10.1016/S2215-0366(17)30328-0 [published Online First: 2017/09/11]
39
40
- 41 10. Ye YY, Zhang YF, Chen J, et al. Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-i)
42 Improves Comorbid Anxiety and Depression-A Meta-Analysis of Randomized Controlled Trials.
43 *PLoS One* 2015;10(11):e0142258. doi: 10.1371/journal.pone.0142258 [published Online First:
44
45 2015/11/19]
46
47
48
- 49 11. Werner-Seidler A, Wong Q, Johnston L, et al. Pilot evaluation of the Sleep Ninja: a smartphone
50 application for adolescent insomnia symptoms. *BMJ open* 2019;9(5):e026502. doi:
51
52 10.1136/bmjopen-2018-026502 [published Online First: 2019/05/28]
53
54
- 55 12. Waloszek JM, Schwartz O, Simmons JG, et al. The SENSE Study (Sleep and Education: learning New
56 Skills Early): a community cognitive-behavioural therapy and mindfulness-based sleep intervention
57 to prevent depression and improve cardiac health in adolescence. *BMC Psychol* 2015;3:39. doi:
58
59 10.1186/s40359-015-0096-x
60

- 1
2
3 13. Blake M, Waloszek JM, Schwartz O, et al. The SENSE study: Post intervention effects of a randomized
4 controlled trial of a cognitive-behavioral and mindfulness-based group sleep improvement
5 intervention among at-risk adolescents. *J Consult Clin Psychol* 2016;84(12):1039-51. doi:
6 10.1037/ccp0000142
7
8
9
- 10
11 14. Blake M, Schwartz O, Waloszek JM, et al. The SENSE Study: Treatment Mechanisms of a Cognitive
12 Behavioral and Mindfulness-Based Group Sleep Improvement Intervention for At-Risk Adolescents.
13 *Sleep* 2017;40(6) doi: 10.1093/sleep/zsx061
14
15
- 16
17 15. Kirschbaum-Lesch I, Gest S, Legenbauer T, et al. Feasibility and Efficacy of Bright Light Therapy in
18 Depressed Adolescent Inpatients. *Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie*
19 2018;46(5):423-29. doi: 10.1024/1422-4917/a000603 [published Online First: 2018/07/18]
20
21
- 22
23 16. de Bruin EJ, Bogels SM, Oort FJ, et al. Improvements of adolescent psychopathology after insomnia
24 treatment: results from a randomized controlled trial over 1 year. *Journal of child psychology and*
25 *psychiatry, and allied disciplines* 2018;59(5):509-22. doi: 10.1111/jcpp.12834 [published Online First:
26 2017/10/21]
27
28
29
- 30
31 17. Dewald-Kaufmann JF, Oort FJ, Meijer AM. The effects of sleep extension and sleep hygiene advice on
32 sleep and depressive symptoms in adolescents: a randomized controlled trial. *Journal of child*
33 *psychology and psychiatry, and allied disciplines* 2014;55(3):273-83. doi: 10.1111/jcpp.12157
34 [published Online First: 2013/11/21]
35
36
- 37
38 18. Fang H, Tu S, Sheng J, et al. Depression in sleep disturbance: A review on a bidirectional relationship,
39 mechanisms and treatment. *J Cell Mol Med* 2019;23(4):2324-32. doi: 10.1111/jcmm.14170
40 [published Online First: 2019/02/09]
41
42
- 43
44 19. Barclay NL, Gehrman PR, Gregory AM, et al. The heritability of insomnia progression during
45 childhood/adolescence: results from a longitudinal twin study. *Sleep* 2015;38(1):109-18. doi:
46 10.5665/sleep.4334 [published Online First: 2014/10/18]
47
48
- 49
50 20. Cole MG, Dendukuri N. Risk factors for depression among elderly community subjects: a systematic
51 review and meta-analysis. *Am J Psychiatry* 2003;160(6):1147-56. doi: 10.1176/appi.ajp.160.6.1147
52 [published Online First: 2003/06/05]
53
54
- 55
56 21. Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic
57 evaluation of longitudinal epidemiological studies. *J Affect Disord* 2011;135(1-3):10-9. doi:
58 10.1016/j.jad.2011.01.011 [published Online First: 2011/02/09]
59
60

- 1
2
3 22. Pigeon WR, Bishop TM, Krueger KM. Insomnia as a Precipitating Factor in New Onset Mental Illness: a
4
5 Systematic Review of Recent Findings. *Curr Psychiatry Rep* 2017;19(8):44. doi: 10.1007/s11920-
6
7 017-0802-x [published Online First: 2017/06/16]
8
9 23. Bao YP, Han Y, Ma J, et al. Cooccurrence and bidirectional prediction of sleep disturbances and
10
11 depression in older adults: Meta-analysis and systematic review. *Neurosci Biobehav Rev*
12
13 2017;75:257-73. doi: 10.1016/j.neubiorev.2017.01.032 [published Online First: 2017/02/10]
14
15 24. Hertenstein E, Feige B, Gmeiner T, et al. Insomnia as a predictor of mental disorders: A systematic
16
17 review and meta-analysis. *Sleep Med Rev* 2019;43:96-105. doi: 10.1016/j.smr.2018.10.006
18
19 [published Online First: 2018/12/12]
20
21 25. Li L, Wu C, Gan Y, et al. Insomnia and the risk of depression: a meta-analysis of prospective cohort
22
23 studies. *BMC Psychiatry* 2016;16(1):375. doi: 10.1186/s12888-016-1075-3 [published Online First:
24
25 2016/11/07]
26
27 26. Roberts RE, Roberts CR, Chen IG. Impact of insomnia on future functioning of adolescents. *J*
28
29 *Psychosom Res* 2002;53(1):561-9. [published Online First: 2002/07/20]
30
31 27. Roane BM, Taylor DJ. Adolescent insomnia as a risk factor for early adult depression and substance
32
33 abuse. *Sleep* 2008;31(10):1351-6. [published Online First: 2008/10/16]
34
35 28. Johnson EO, Chilcoat HD, Breslau N. Trouble sleeping and anxiety/depression in childhood. *Psychiatry*
36
37 *Res* 2000;94(2):93-102. [published Online First: 2000/05/16]
38
39 29. Alvaro PK, Roberts RM, Harris JK, et al. The direction of the relationship between symptoms of insomnia
40
41 and psychiatric disorders in adolescents. *J Affect Disord* 2017;207:167-74. doi:
42
43 10.1016/j.jad.2016.08.032 [published Online First: 2016/10/11]
44
45 30. Ritter PS, Hofler M, Wittchen HU, et al. Disturbed sleep as risk factor for the subsequent onset of bipolar
46
47 disorder--Data from a 10-year prospective-longitudinal study among adolescents and young adults. *J*
48
49 *Psychiatr Res* 2015;68:76-82. doi: 10.1016/j.jpsychires.2015.06.005 [published Online First:
50
51 2015/08/01]
52
53 31. Hayley AC, Skogen JC, Sivertsen B, et al. Symptoms of Depression and Difficulty Initiating Sleep from
54
55 Early Adolescence to Early Adulthood: A Longitudinal Study. *Sleep* 2015;38(10):1599-606. doi:
56
57 10.5665/sleep.5056 [published Online First: 2015/07/22]
58
59 32. Armstrong JM, Ruttle PL, Klein MH, et al. Associations of child insomnia, sleep movement, and their
60
persistence with mental health symptoms in childhood and adolescence. *Sleep* 2014;37(5):901-9.
doi: 10.5665/sleep.3656 [published Online First: 2014/05/03]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

33. Armitage R, Hoffmann RF, Emslie GJ, et al. Sleep microarchitecture as a predictor of recurrence in children and adolescents with depression. *Int J Neuropsychopharmacol* 2002;5(3):217-28. doi: 10.1017/S1461145702002948 [published Online First: 2002/10/09]
34. Gregory AM, O'Connor TG. Sleep problems in childhood: a longitudinal study of developmental change and association with behavioral problems. *J Am Acad Child Adolesc Psychiatry* 2002;41(8):964-71. doi: 10.1097/00004583-200208000-00015 [published Online First: 2002/08/07]
35. Fredriksen K, Rhodes J, Reddy R, et al. Sleepless in Chicago: tracking the effects of adolescent sleep loss during the middle school years. *Child Dev* 2004;75(1):84-95. [published Online First: 2004/03/16]
36. Gregory AM, Caspi A, Eley TC, et al. Prospective longitudinal associations between persistent sleep problems in childhood and anxiety and depression disorders in adulthood. *J Abnorm Child Psychol* 2005;33(2):157-63. [published Online First: 2005/04/21]
37. Gregory AM, Van der Ende J, Willis TA, et al. Parent-reported sleep problems during development and self-reported anxiety/depression, attention problems, and aggressive behavior later in life. *Arch Pediatr Adolesc Med* 2008;162(4):330-5. doi: 10.1001/archpedi.162.4.330 [published Online First: 2008/04/09]
38. Gregory AM, Rijdsdijk FV, Lau JY, et al. The direction of longitudinal associations between sleep problems and depression symptoms: a study of twins aged 8 and 10 years. *Sleep* 2009;32(2):189-99. doi: 10.1093/sleep/32.2.189 [published Online First: 2009/02/26]
39. Touchette E, Chollet A, Galera C, et al. Prior sleep problems predict internalising problems later in life. *J Affect Disord* 2012;143(1-3):166-71. doi: 10.1016/j.jad.2012.05.049 [published Online First: 2012/08/04]
40. Greene G, Gregory AM, Fone D, et al. Childhood sleeping difficulties and depression in adulthood: the 1970 British Cohort Study. *J Sleep Res* 2015;24(1):19-23. doi: 10.1111/jsr.12200 [published Online First: 2014/09/03]
41. Wang B, Eastwood PR, Becker A, et al. Concurrent developmental course of sleep problems and emotional/behavioral problems in childhood and adolescence as reflected by the dysregulation profile. *Sleep* 2019;42(3) doi: 10.1093/sleep/zsy243 [published Online First: 2018/12/07]
42. Wang B, Isensee C, Becker A, et al. Developmental Trajectories of Sleep Problems from Childhood to Adolescence Both Predict and Are Predicted by Emotional and Behavioral Problems. *Front Psychol* 2016;7:1874. doi: 10.3389/fpsyg.2016.01874 [published Online First: 2016/12/19]

- 1
2
3 43. McCracken JT, Poland RE, Lutchmansingh P, et al. Sleep electroencephalographic abnormalities in
4
5 adolescent depressives: effects of scopolamine. *Biol Psychiatry* 1997;42(7):577-84. doi:
6
7 10.1016/S0006-3223(96)00431-3 [published Online First: 1997/10/06]
8
9 44. Rao U, McCracken JT, Lutchmansingh P, et al. Electroencephalographic sleep and urinary free cortisol
10
11 in adolescent depression: a preliminary report of changes from episode to recovery. *Biol Psychiatry*
12
13 1997;41(3):369-73. [published Online First: 1997/02/01]
14
15 45. Rao U, Dahl RE, Ryan ND, et al. The relationship between longitudinal clinical course and sleep and
16
17 cortisol changes in adolescent depression. *Biol Psychiatry* 1996;40(6):474-84. doi: 10.1016/0006-
18
19 3223(95)00481-5 [published Online First: 1996/09/15]
20
21 46. Rao U, Dahl RE, Ryan ND, et al. Heterogeneity in EEG sleep findings in adolescent depression: unipolar
22
23 versus bipolar clinical course. *J Affect Disord* 2002;70(3):273-80. [published Online First:
24
25 2002/07/20]
26
27 47. Rao U, Poland RE. Electroencephalographic sleep and hypothalamic-pituitary-adrenal changes from
28
29 episode to recovery in depressed adolescents. *J Child Adolesc Psychopharmacol* 2008;18(6):607-
30
31 13. doi: 10.1089/cap.2008.034 [published Online First: 2008/12/26]
32
33 48. Shain BN, Naylor M, Shipley JE, et al. Imipramine effects on sleep in depressed adolescents: a
34
35 preliminary report. *Biol Psychiatry* 1990;28(5):459-62. [published Online First: 1990/09/01]
36
37 49. Goetz RR, Wolk SI, Coplan JD, et al. Premorbid polysomnographic signs in depressed adolescents: a
38
39 reanalysis of EEG sleep after longitudinal follow-up in adulthood. *Biol Psychiatry* 2001;49(11):930-
40
41 42. [published Online First: 2001/05/30]
42
43 50. Lovato N, Gradisar M. A meta-analysis and model of the relationship between sleep and depression in
44
45 adolescents: recommendations for future research and clinical practice. *Sleep Med Rev*
46
47 2014;18(6):521-9. doi: 10.1016/j.smrv.2014.03.006 [published Online First: 2014/05/27]
48
49 51. Zisapel N. Paediatric use of melatonin: Letter to the Editor regarding the manuscript "Current role of
50
51 melatonin in pediatric neurology: Clinical recommendations" by Bruni et al. *Eur J Paediatr Neurol*.
52
53 2015 Mar;19(2):122-33. *Eur J Paediatr Neurol* 2017;21(2):418-19. doi: 10.1016/j.ejpn.2016.07.013
54
55 [published Online First: 2016/08/16]
56
57 52. Bruni O, Alonso-Alconada D, Besag F, et al. Current role of melatonin in pediatric neurology: clinical
58
59 recommendations. *Eur J Paediatr Neurol* 2015;19(2):122-33. doi: 10.1016/j.ejpn.2014.12.007
60
[published Online First: 2015/01/03]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

53. Ma ZR, Shi LJ, Deng MH. Efficacy of cognitive behavioral therapy in children and adolescents with insomnia: a systematic review and meta-analysis. *Braz J Med Biol Res* 2018;51(6):e7070. doi: 10.1590/1414-431x20187070 [published Online First: 2018/05/24]
54. Kalak N, Gerber M, Kirov R, et al. Daily morning running for 3 weeks improved sleep and psychological functioning in healthy adolescents compared with controls. *J Adolesc Health* 2012;51(6):615-22. doi: 10.1016/j.jadohealth.2012.02.020 [published Online First: 2012/11/24]
55. van Maanen A, Meijer AM, Smits MG, et al. Effects of Melatonin and Bright Light Treatment in Childhood Chronic Sleep Onset Insomnia With Late Melatonin Onset: A Randomized Controlled Study. *Sleep* 2017;40(2) doi: 10.1093/sleep/zsw038 [published Online First: 2017/04/02]
56. Meltzer LJ, Johnson C, Crosette J, et al. Prevalence of diagnosed sleep disorders in pediatric primary care practices. *Pediatrics* 2010;125(6):e1410-8. doi: 10.1542/peds.2009-2725 [published Online First: 2010/05/12]
57. Meltzer LJ, Plaufcan MR, Thomas JH, et al. Sleep problems and sleep disorders in pediatric primary care: treatment recommendations, persistence, and health care utilization. *J Clin Sleep Med* 2014;10(4):421-6. doi: 10.5664/jcsm.3620 [published Online First: 2014/04/16]
58. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1. doi: 10.1186/2046-4053-4-1 [published Online First: 2015/01/03]
59. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000;283(15):2008-12. doi: 10.1001/jama.283.15.2008 [published Online First: 2000/05/02]
60. Viswanathan M, Berkman ND. Development of the RTI item bank on risk of bias and precision of observational studies. *J Clin Epidemiol* 2012;65(2):163-78. doi: 10.1016/j.jclinepi.2011.05.008 [published Online First: 2011/10/01]
61. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21(11):1539-58. doi: 10.1002/sim.1186 [published Online First: 2002/07/12]
62. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. *Int J Epidemiol* 2008;37(5):1148-57. doi: 10.1093/ije/dyn065 [published Online First: 2008/04/22]
63. Gregory AM, Sadeh A. Sleep, emotional and behavioral difficulties in children and adolescents. *Sleep Med Rev* 2012;16(2):129-36. doi: 10.1016/j.smr.2011.03.007 [published Online First: 2011/06/17]

- 1
2
3 64. Rao U, Chen LA. Characteristics, correlates, and outcomes of childhood and adolescent depressive
4 disorders. *Dialogues Clin Neurosci* 2009;11(1):45-62. [published Online First: 2009/05/13]
5
6
7 65. Galland BC, Taylor BJ, Elder DE, et al. Normal sleep patterns in infants and children: a systematic
8 review of observational studies. *Sleep Med Rev* 2012;16(3):213-22. doi: 10.1016/j.smrv.2011.06.001
9 [published Online First: 2011/07/26]
10
11
12 66. Tarokh L, Saletin JM, Carskadon MA. Sleep in adolescence: Physiology, cognition and mental health.
13 *Neurosci Biobehav Rev* 2016;70:182-88. doi: 10.1016/j.neubiorev.2016.08.008 [published Online
14 First: 2016/10/22]
15
16
17
18 67. Jenni OG, Molinari L, Cafilisch JA, et al. Sleep duration from ages 1 to 10 years: variability and stability in
19 comparison with growth. *Pediatrics* 2007;120(4):e769-76. doi: 10.1542/peds.2006-3300 [published
20 Online First: 2007/10/03]
21
22
23
24 68. Iglowstein I, Jenni OG, Molinari L, et al. Sleep duration from infancy to adolescence: reference values
25 and generational trends. *Pediatrics* 2003;111(2):302-7. doi: 10.1542/peds.111.2.302 [published
26 Online First: 2003/02/04]
27
28
29
30 69. Hummer DL, Lee TM. Daily timing of the adolescent sleep phase: Insights from a cross-species
31 comparison. *Neurosci Biobehav Rev* 2016;70:171-81. doi: 10.1016/j.neubiorev.2016.07.023
32 [published Online First: 2016/10/22]
33
34
35
36 70. Matricciani L, Olds T, Petkov J. In search of lost sleep: secular trends in the sleep time of school-aged
37 children and adolescents. *Sleep Med Rev* 2012;16(3):203-11. doi: 10.1016/j.smrv.2011.03.005
38 [published Online First: 2011/05/27]
39
40
41
42 71. Keyes KM, Maslowsky J, Hamilton A, et al. The great sleep recession: changes in sleep duration among
43 US adolescents, 1991-2012. *Pediatrics* 2015;135(3):460-8. doi: 10.1542/peds.2014-2707 [published
44 Online First: 2015/02/18]
45
46
47
48 72. Adolescent Sleep Working G, Committee on A, Council on School H. School start times for adolescents.
49 *Pediatrics* 2014;134(3):642-9. doi: 10.1542/peds.2014-1697 [published Online First: 2014/08/27]
50
51
52
53 73. Stiglic N, Viner RM. Effects of screentime on the health and well-being of children and adolescents: a
54 systematic review of reviews. *BMJ open* 2019;9(1):e023191. doi: 10.1136/bmjopen-2018-023191
55 [published Online First: 2019/01/05]
56
57
58
59
60

Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Reporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4(1):1.

Reporting Item			Page Number
Title			
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	n/a
Registration			
	#2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors			
Contact	#3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	#3b	Describe contributions of protocol authors and identify the guarantor of the review	12
Amendments			

1	#4	If the protocol represents an amendment of a previously completed or	n/a
2		published protocol, identify as such and list changes; otherwise, state	
3		plan for documenting important protocol amendments	
4			
5			
6	Support		
7			
8	Sources	#5a Indicate sources of financial or other support for the review	12
9			
10	Sponsor	#5b Provide name for the review funder and / or sponsor	n/a
11			
12	Role of sponsor or	#5c Describe roles of funder(s), sponsor(s), and / or institution(s), if any,	12
13	funder	in developing the protocol	
14			
15			
16	Introduction		
17			
18	Rationale	#6 Describe the rationale for the review in the context of what is already	3-5
19		known	
20	Objectives	#7 Provide an explicit statement of the question(s) the review will	6
21		address with reference to participants, interventions, comparators, and	
22		outcomes (PICO)	
23			
24			
25			
26			
27			
28	Methods		
29			
30	Eligibility criteria	#8 Specify the study characteristics (such as PICO, study design, setting,	6-7
31		time frame) and report characteristics (such as years considered,	
32		language, publication status) to be used as criteria for eligibility for	
33		the review	
34			
35			
36			
37	Information sources	#9 Describe all intended information sources (such as electronic	8
38		databases, contact with study authors, trial registers or other grey	
39		literature sources) with planned dates of coverage	
40			
41			
42			
43	Search strategy	#10 Present draft of search strategy to be used for at least one electronic	8
44		database, including planned limits, such that it could be repeated	
45			
46			
47	Study records - data	#11a Describe the mechanism(s) that will be used to manage records and	9
48	management	data throughout the review	
49			
50	Study records -	#11b State the process that will be used for selecting studies (such as two	9
51	selection process	independent reviewers) through each phase of the review (that is,	
52		screening, eligibility and inclusion in meta-analysis)	
53			
54			
55			
56	Study records - data	#11c Describe planned method of extracting data from reports (such as	10
57	collection process	piloting forms, done independently, in duplicate), any processes for	
58			
59			
60			

		obtaining and confirming data from investigators	
1			
2			
3	Data items	#12 List and define all variables for which data will be sought (such as	10
4		PICO items, funding sources), any pre-planned data assumptions and	
5		simplifications	
6			
7			
8	Outcomes and	#13 List and define all outcomes for which data will be sought, including	9-10
9	prioritization	prioritization of main and additional outcomes, with rationale	
10			
11			
12	Risk of bias in	#14 Describe anticipated methods for assessing risk of bias of individual	10
13	individual studies	studies, including whether this will be done at the outcome or study	
14		level, or both; state how this information will be used in data synthesis	
15			
16			
17	Data synthesis	#15a Describe criteria under which study data will be quantitatively	10-11
18		synthesised	
19			
20			
21	Data synthesis	#15b If data are appropriate for quantitative synthesis, describe planned	10-11
22		summary measures, methods of handling data and methods of	
23		combining data from studies, including any planned exploration of	
24		consistency (such as I ² , Kendall's τ)	
25			
26			
27			
28	Data synthesis	#15c Describe any proposed additional analyses (such as sensitivity or	10-11
29		subgroup analyses, meta-regression)	
30			
31	Data synthesis	#15d If quantitative synthesis is not appropriate, describe the type of	10-11
32		summary planned	
33			
34			
35	Meta-bias(es)	#16 Specify any planned assessment of meta-bias(es) (such as publication	10-11
36		bias across studies, selective reporting within studies)	
37			
38			
39	Confidence in	#17 Describe how the strength of the body of evidence will be assessed	11
40	cumulative	(such as GRADE)	
41	evidence		
42			
43			

The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. This checklist was completed on 26. September 2019 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Do insomnia and/or sleep disturbances predict the onset, relapse or worsening of depression in community and clinical samples of children and youth? Protocol for a systematic review and meta-analysis.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034606.R1
Article Type:	Protocol
Date Submitted by the Author:	15-May-2020
Complete List of Authors:	marino, cecilia; Centre for Addiction and Mental Health, Andrade, Brendan; University of Toronto Department of Psychiatry, Aitken, Madison; Centre for Addiction and Mental Health Bonato, Sarah; Centre for Addiction and Mental Health Centre for Addiction and Mental Health, Library Services Haltigan, John; Centre for Addiction and Mental Health Wang, Wei; Centre for Addiction and Mental Health Szatmari, Peter; Centre for Addiction and Mental Health
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Mental health
Keywords:	SLEEP MEDICINE, Depression & mood disorders < PSYCHIATRY, Child & adolescent psychiatry < PSYCHIATRY, longitudinal studies, systematic review

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 Do insomnia and/or sleep disturbances predict the onset, relapse or worsening of depression in community
4 and clinical samples of children and youth? Protocol for a systematic review and meta-analysis.
5
6
7

8
9 Cecilia Marino^{1,2}, Brendan Andrade^{1,2}, Madison Aitken,^{1,2} Sarah Bonato¹, John Haltigan^{1,2}, Wei Wang^{1,2} and
10 Peter Szatmari^{1,2,3}

11
12 ¹ Cundill Centre for Child and Youth Depression, Center for Addiction and Mental Health, Toronto, Canada

13
14 ² Department of Psychiatry, University of Toronto, Toronto, Canada

15
16 ³ Hospital for Sick Children, Toronto, Ontario, Canada

17
18 Corresponding author: Cecilia Marino, Centre for Addiction and Mental Health (CAMH), 80 Workman Way,
19 Room 1236, Toronto, ON M6J 1H4, e-mail: cecilia.marino@utoronto.ca, Tel: 416-535-8501 Ext. 35134

20
21
22 Brendan Andrade, Brendan.Andrade@camh.ca

23
24 Madison Aitken, Madison.Aitken@camh.ca

25
26 Sarah Bonato, Sarah.Bonato@camh.ca

27
28 John Haltigan, John.Haltigan@camh.ca

29
30 Wei Wang, Wei.Wang@camh.ca

31
32 Peter Szatmari, peter.szatmari@utoronto.ca
33
34
35
36
37
38

39 Abstract

40 Introduction

41
42 Disturbed sleep represents a potentially important modifiable risk factor for the development of depression
43 in children and youth. This protocol for a systematic review proposes to investigate whether insomnia
44 and/or sleep disturbances predict child and youth depression in community and clinical-based samples.
45
46
47
48

49 Methods and analysis

50
51 The protocol adheres to the Preferred Reporting Items for Systematic Review and Meta-Analysis protocols
52 (PRISMA-P) guidelines. English-written, longitudinal studies that quantitatively estimated the prediction of
53 depression by insomnia and/or sleep disturbances in individuals 5-24 years of age will be included.
54
55 EMBASE, MEDLINE, PsychINFO, Scopus and Web of Science and grey literature will be searched from
56 1980 to the present. For the selection of studies, two reviewers will be involved. Data extraction will be
57
58 conducted by one author and checked independently by a second author. Risk of bias will be appraised
59
60

1
2
3 using the Research Triangle Institute Item Bank (RTI-IB) tool. Heterogeneity will be measured using the I^2
4
5 statistic. Meta-analysis will be carried out if ≥ 3 results are available and if outcome measures can be
6
7 pooled. The choice between a random-effect or fixed-effect model will be based both on the I^2 statistics and
8
9 the participant-level characteristics of the combined studies. Results of the meta-analyses will be
10
11 summarized by a forest plot. Analyses will be performed in subgroups stratified by key variables defined
12
13 depending on the amount and type of information retrieved.

14
15 A narrative synthesis will be conducted in place of the meta-analysis, should pooling of data not be
16
17 possible. Quality of evidence will be rated using the Grading of Recommendations Assessment,
18
19 Development, and Evaluation (GRADE) guidelines.

20
21 As this is a protocol for systematic review and meta-analysis of published data, ethics review and approval
22
23 are not required. The findings will be published in a peer-reviewed journal and disseminated at scientific
24
25 conferences and to patient advocacy organizations.

26 27 28 29 30 Strengths and limitations of this study

- 31
32 • This is a protocol for a systematic review and meta-analysis of existing prospective, longitudinal
33
34 evidence on insomnia and/or sleep disturbances predicting depression in children and youth.
 - 35
36 • This protocol will adhere to the Preferred Reporting Items for Systematic review and Meta-Analysis
37
38 protocols (PRISMA-P) guidelines
 - 39
40 • This protocol is registered at PROSPERO, the international prospective register of systematic
41
42 reviews
 - 43
44 • Full-text screening and extraction will be performed by two reviewers. Any uncertainty regarding
45
46 selection will be resolved by consensus and if necessary, by a third reviewer.
 - 47
48 • With regards to limitations, the review will not include treatment studies and will include only
49
50 English-written articles. We include individuals aged 5-24 years, therefore excluding studies on
51
52 child and youth disturbed sleep predicting depression at later stages of life.
- 53
54
55
56
57
58

59 Trial registration number: International Prospective Register for Systematic Reviews (PROSPERO)
60 registration number CRD42019136729.

Introduction

A recent epidemiological study analyzing data from the 2016 National Survey of Children's Health reports prevalence estimates of depression of 1.7% and 6.1% in 6-11 and 12-17 years age-ranges, respectively.¹

The incidence of depression peaks at 20 years of age² with disrupting effects on normative developmental trajectories. Prevalence is equal for both sexes prior to puberty, then it is higher in females.³ Treatment shows limited efficacy,⁴⁻⁶ suggesting that prevention may be a more effective resource to reduce the incidence of depression.

Targeting modifiable risk factors of illnesses is becoming a relevant therapeutic strategy for disease prevention.⁷ Among modifiable risk factors predicting child and youth depression, insomnia is increasingly recognized as an important component of the complex and multi-factorial causal pathway of depression.⁸ Treating insomnia to specifically reduce the incidence and/or severity of depression has been the focus of controlled, high quality, randomized treatment studies in depressed or at risk for depression adult or elderly individuals.⁹⁻¹⁰ In a recent meta-analysis, internet-based cognitive behavioural therapy (CBT) for insomnia had a significant, small effect on comorbid depression in individuals older than 18 years.¹¹

Similar evidence in younger individuals is scarce, mostly consists of studies with small sample size/no follow-up, and it is limited to individuals older than 12 years of age¹²⁻¹⁸.

In a randomized controlled trial, CBT for insomnia for six weekly sessions and a booster session after 2 months was significantly more effective in decreasing comorbid depression compared to waitlist in 12-19-year-old individuals with DSM-5 insomnia and no comorbid psychiatric disorders. The effect was large, was maintained after 12 months, and was fully mediated by the reduction of insomnia symptoms.¹⁷

In a longitudinal, randomised controlled trial study (SENSE, i.e. Sleep and Education: learning New Skills Early) the preventative effect on the incidence of depression in at risk for depression, 12-17-year-old adolescents with sleeping difficulties is investigated.¹³ The interventions consist of seven weekly sessions of either a CBT/mindfulness-based sleep intervention or an active control intervention, followed by two booster sessions after three and six months post-intervention. One-hundred-twenty-three participants have completed the interventions,¹⁴⁻¹⁵ however findings regarding the main outcomes of the study (preventative effects of depression) from the two-year follow-up are not available yet.

It is currently not known whether treating sleep problems in depressed or at risk for depression children (e.g. children with history of abuse, with high emotional dysregulation, offspring of depressed parents)

1
2
3 would lead to a reduction or lower incidence of depression, respectively, than it would be if sleep problems
4 were not treated.¹⁹ To understand whether earlier prevention efforts could be more effective, a precise
5 quantitative estimate of the prediction of depression by insomnia in the entire developmental population,
6 including depressed and non-depressed individuals, is needed.
7
8
9

10
11 Insomnia consists of clinically significant long sleep-onset latency and/or awakening after sleep onset
12 and/or early-morning awakening, accompanied by diurnal tiredness and functional impairment. Prevalence
13 of insomnia is 19.5% in children, equally distributed among boys and girls; in youth, prevalence is 17.4%,
14 and higher among girls.²⁰
15
16
17

18
19 Six systematic reviews have summarized cohort studies on insomnia predicting depression.²¹⁻²⁵ Pooled
20 estimates are consistent across reviews ranging 2.10 (95% CI= 1.86-2.38)²⁶-2.83 (95% CI= 1.55-5.17)²⁴,
21 and across subgroups stratified by the most common confounders, e.g. sex [male: 1.46 (95% CI= 1.13-
22 1.88)²⁵; females: 1.96 (95% CI= 1.05-3.66)²⁵], type of ascertainment [non-general population: 2.05 (95%
23 CI= 1.53-2.74)²⁵; general population: 2.34 (95% CI= 1.85-2.96)²⁵], and age [individuals of age \geq 60 years:
24 1.87 (95% CI= 1.47, 2.37)²⁵-1.92 (95% CI: 1.61-2.30)²³; individuals younger than 60 years of age: 2.50
25 (95% CI= 1.96, 3.20)²⁵].
26
27
28
29
30
31

32
33 However, only three of the six systematic reviews included participants younger than 18 years,^{22 25 26} and a
34 pooled estimate, i.e. odds ratio= 2.0 (95% CI= 1.5-2.7), was provided by only one of the three reviews.²⁶
35

36
37 This estimate was based on three studies up to 2010 and included 7404 participants, whose age ranged
38 between 6 and 16 years.²⁷⁻²⁹ In all three studies, depression was defined according to DSM IV, and
39 insomnia to DSM-IV-TR criteria. The test for heterogeneity for this group did not show a significant index
40 (Q-value= 0.3; df(Q)=2; p=0.9; and I²=0.0). Li et al.²⁵ updated and used the same selection criteria of
41 Baglioni et al.²⁶ and although fifteen new cohort studies were added, no new studies on children and youth
42 were included. Finally, Pigeon et al.²² summarized studies published from 2014 to 2017; four studies on
43 children and youth were included, of which three supported insomnia predicting depression,³⁰⁻³² and one
44 found no such association.³³ All three systematic reviews of this age group excluded studies which did not
45 control for baseline depression. This led to a greatly reduced number of studies. While the rationale of this
46 choice is clear for studies of risk and prediction, it might not have been the ideal choice, due to the overall
47 paucity of studies in the child and youth age-range compared to other age groups. Including studies that did
48 not control for baseline depression would allow testing of whether there are significant differences in the
49 meta-analytic estimates between studies controlling versus not-controlling for this variable. If no differences
50
51
52
53
54
55
56
57
58
59
60

1
2
3 are found, studies not controlling for baseline depression could contribute to the pooled data with an overall
4 increase of the precision for the estimate of the meta-analytic effects.
5

6
7 There is also some evidence available on whether sleep disturbances other than insomnia predicts child
8 and youth depression.³⁴⁻⁴³ This may include increased/short/disrupted sleep duration with/without diurnal
9 sleepiness, sleepwalking/talking, nightmares, bedwetting, breathing-related sleep disorders, and/or
10 circadian disturbances. Furthermore, sleep disturbances more broadly defined may include challenges
11 either generically defined with regards to duration and consistency over time, measured by self-reported
12 questionnaires, interview or by EEG/actigraph-based measures, and scored by either single-item or
13 cumulative scores. A recent meta-analysis summarized studies testing the association of broadly defined
14 sleep disturbances on depression in 12-20-year-old already clinically depressed participants. In all selected
15 studies,⁴⁴⁻⁵⁰ sleep was defined by EEG-based, objective measures. Estimates of the meta-analytic effects
16 identified that EEG-based longer sleep onset latency, more wake after sleep onset and lower sleep efficiency
17 were significant predictors of depression compared to typical sleep (effect sizes ranging .43-.58).⁵¹
18

19
20 Although findings from this review are of crucial importance for potential secondary prevention programs in
21 depressed youth, it would be useful to have summarized data on the longitudinal association of broadly
22 defined sleep disturbances with depression on the entire developmental population, including non-clinical
23 individuals as well as a broader age range, which would allow to apply findings to primary prevention and/or
24 early intervention programs.
25

26
27 Finally, insomnia and/or sleep disturbances are often associated to comorbid psychiatric and medical
28 conditions.¹⁹ Most previous knowledge synthesis studies have excluded comorbidities, limiting the
29 generalizability and transferability of findings. For this reason, in this systematic review studies focusing on
30 both primary and comorbid insomnia and/or sleep disturbances will be included. To understand the extent
31 to which insomnia and/or sleep disturbances have a distinct risk to depression across comorbid disorders,
32 subgroup analyses will be performed.
33

34
35 Understanding whether insomnia and/or sleep disturbances significantly increase the risk of depression in
36 children and youth could lead to variation in clinical practice and inform policy development. Preventive
37 strategies could include treating sleep problems starting as early as childhood. This is particularly important
38 in light of evidence on the differential effectiveness of a number of treatment for sleep problems (e.g.
39 melatonin,^{52 53} cognitive behavioural therapy,⁵⁴ physical exercise,⁵⁵ and bright light therapy⁵⁶) and the fact
40 that sleep problems in children are under-diagnosed⁵⁷ and rarely treated.⁵⁸
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The purpose of this protocol is to outline methods for a systematic review and meta-analysis of data from
4 prospective, longitudinal studies of children and youth ascertained from clinical or community-based
5 samples investigating the role of insomnia and/or sleep disturbances compared to typical sleep as
6 predictors of depression. “Do children and youth with insomnia and/or sleep disturbance have higher rates
7 of later depression than children and youth without insomnia and/or sleep disturbance”?
8
9
10
11

12 We are interested in testing this relationship in the context of both the absence and presence of baseline
13 depression, i.e. whether insomnia and/or sleep disturbance predict both new and relapse/worsening of
14 depression, respectively.
15
16
17

18 Our study will add to the currently available knowledge synthesis in that:
19

- 20 1. It will provide an updated meta-analytic estimate of the effects of insomnia predicting child and
21 youth depression, adding studies from 2010 onward compared to Baglioni et al.²⁶
22
23
- 24 2. By including studies on 5-24-year-old participants from both clinical and non-clinical populations, it
25 will provide a more comprehensive and updated meta-analytic estimate compared to Lovato and
26 Gradisar⁵¹
27
28
- 29 3. It will include studies on participants with/without baseline depression and whether or not controlling
30 for baseline depression
31
32
- 33 4. It will include studies of both primary and comorbid insomnia and/or sleep disturbances
34
35

36 As a secondary aim, we will test whether insomnia and/or sleep disturbance predict new onset and/or
37 worsening/relapse of depression, by testing the pooled estimate in two subgroups of studies, respectively,
38 those including participants with baseline depression or where baseline depression has been controlled for,
39 and studies including participants without baseline depression or where baseline depression has not been
40 controlled for.
41
42
43
44

45 Finally, we aim to explore the sources of potential heterogeneity and examine the robustness of the primary
46 hypothesis against key confounding variables. Specifically, we will address whether the prediction of child
47 and youth depression by insomnia and/or sleep disturbances significantly differ between studies stratified by
48 key variables, e.g. risk of bias score, type of ascertainment, type of sleep disturbance, measurement of
49 outcome, presence of baseline comorbidity, sample size, age group, gender. Subgroups will be defined
50 depending on the amount and type of information retrieved.
51
52
53
54
55

56 **Methods**
57
58
59
60

1
2
3 For the protocol, we will follow the guidelines outlined in “Preferred Reporting Items for Systematic review
4 and Meta-Analysis protocols (PRISMA-P)”.⁵⁹ For the final report we will follow the guidelines set in “Meta-
5 analysis Of Observational Studies in Epidemiology: a proposal for reporting” (MOOSE).⁶⁰
6
7
8
9

10 Inclusion criteria

14 *Study types*

16 This study will include (1) English-written, (2) prospective, longitudinal observational studies that
17 quantitatively estimated the prediction of depression by insomnia and/or sleep disturbances in children and
18 youth. Only those studies reporting odds ratio, relative risk, hazard ratio, regression coefficients or
19 correlation coefficients with their respective measurements of error and p-values will be selected. Grey
20 literature including relevant dissertations/PhD theses and key conference publications will be included. Case
21 series, case reports, systematic reviews, meta-analyses, as well as experimental, retrospective, cross-
22 sectional, treatment, theoretical and position studies will be excluded.
23
24
25
26
27
28
29
30

31 *Population type*

33 Mean age to determine eligibility for inclusion of the study is between 5-24 years. This age range was
34 chosen to cover the whole age range of risk for depression in childhood and youth, and to include the period
35 of peak incidence for depression.^{1 2} In our review, we identify three categories: ‘childhood’ between 5 and 9
36 years of age, ‘adolescence’ between 10 and 19 years of age, and ‘young adulthood’ between 20 and 24
37 years of age.⁶¹ For simplicity, the term ‘youth’ refers to individuals whose age is between 10 and 24 years.
38
39
40
41
42
43 Studies focusing on participants belonging to either community or clinical based samples with any comorbid
44 psychiatric/neurological/medical diagnosis will be included.
45
46
47
48

49 *Exposure*

51 Studies will be included if focusing on either one of the following two exposures:

- 53 1. Insomnia, defined as clinically significant difficulty in initiating or maintaining sleep or non-restorative
54 sleep, as based on DSM III and later versions. Although the criterion of daytime impairment is
55 required to define clinically significant insomnia, it has been shown that pooled estimates of
56 insomnia predicting depression when this criterion is taken into account²⁴ is of comparable
57 magnitude relative to the ones obtained when this criterion is not considered (Baglioni et al. 2011;
58
59
60

1
2
3 Li et al. 2016).²⁶ Therefore, to allow for inclusion of the highest number of studies, daytime
4 impairment will be free to vary.
5

- 6
7 2. Sleep disturbances, defined as patterns of quality and sleep duration which deviate from expected
8 age-related norms, i.e. increased/short/fragmented sleep duration with or without daytime
9 fatigue/sleepiness, nightmares/terror attacks, circadian disturbances, and/or night walking/talking.
10 Sleep disturbances can be generically defined with regards to duration and consistency over time,
11 and can be based on subjective and/or EEG/actigraph-based, objective measures. Measures can
12 be based on single or multiple items, or a cumulative score of various items. To increase the
13 generalizability of the results, narcolepsy, breathing-related sleep disorders, central sleep apnea,
14 non-rapid/rapid eye movement sleep disorder, restless legs syndrome, substance/medication-
15 induced sleep disorder, and enuresis nocturna primaria may also be included.
16
17
18
19
20
21
22
23

24 Exposures' assessment can be administered by a clinician, a researcher, or based on self-report, parent-
25 report, and/or teacher-report questionnaires.
26
27
28
29

30 *Outcome*

31 Studies will be included if they focus on either one of the following outcomes: major depressive disorder,
32 depressive disorder not otherwise specified, dysthymic disorder, and/or dimensional constructs of
33 depression, i.e. defined by scores from single- or multiple-item questionnaires, internalizing disorders or
34 anxious depression. Studies focusing on anxiety without a measure of depression will not be included.
35
36
37
38

39 Studies including participants with bipolar disorders will be excluded given that sleep problems' prevalence
40 differ significantly in bipolar versus unipolar disorders.^{47 62} Outcome is measured by standardized and
41 validated tools administered by a clinician, a researcher, and/or based on self-report, parent-report, and/or
42 teacher-report questionnaires.
43
44
45
46

47 To be included, both exposure and outcome have to be measured at mean age ≥ 5 years and ≤ 24 and the
48 time between the exposure and outcome is \geq one month. To address the research question on the role of
49 insomnia and/or sleep disturbances as predictor of depression, only studies reporting on the exposure
50 measured at least one month before the outcome will be included. When multiple assessments are
51 conducted on the same cohort, each pair where both exposures and outcomes are measured at mean age \leq
52 24 and ≥ 5 years and exposures are measured before the outcome will be considered.
53
54
55
56
57
58
59
60

Confounders

1
2
3 Studies will be included regardless of whether they contain estimates adjusted for common confounding
4 factors, such as sex, socio-economic status, demographics, type of comorbidity at baseline. Studies that do
5 not control for common confounding factors will be highlighted for potentially confounded results.
6
7
8
9

10 Identification of eligible studies and data extraction

11 *Search strategy*

12
13 The following databases will be searched: EMBASE, MEDLINE, PsychINFO, Scopus and Web of Science. A
14 draft of the Medline search strategy will be developed using a combination of MeSH and keywords terms
15 relating to sleep disorders, depression/depressive disorder and children/adolescents/young adults with the
16 help of a research librarian. The search will be limited to the years 1980 (to focus on current diagnostic
17 terminology from the DSM III) to the present and will also be limited to observational studies using the search
18 filter developed by the Scottish Intercollegiate Guidelines Network (SIGN). The draft Medline search will also
19 be piloted to ensure the sensitivity and efficacy of the final search strategy and will also be reviewed by all of
20 the participating authors (figure 1). The finalized Medline search will be adapted for each bibliographic
21 database individually.
22
23
24
25
26
27
28
29

30
31 Grey literature, i.e. dissertations and conference proceeding/papers, will be included in the search in order to
32 mitigate against publication bias.⁶³ Dissertations have been noted as providing a valuable methodology and
33 clinical source of information.⁶⁴ Additionally, searching for relevant conference proceedings/papers is
34 recommended in order to identify recent, but unpublished research.⁶⁵
35
36
37
38
39

40 The grey literature will be screened for relevant material, including use of the search checklist Grey Matters:
41 “A Practical Search Tool for Evidence-Based Medicine” from the Canadian Agency for Drugs and
42 Technologies in Health (CADTH), and by also searching other sources to identify relevant dissertations/PhD
43 theses and conference publications, i.e. Proquest Dissertations and Theses, ProceedingsFirst, PapersFirst,
44 Conference Abstracts from Embase, Google Scholar Search. The references of selected articles will also be
45 hand-searched for eligible studies and all the searches will be re-run just before the final analyses to identify
46 additional relevant studies. Experts in the field will be contacted to locate potentially eligible studies and/or
47 unpublished data.
48
49
50
51
52
53
54
55

56 *Selection of studies*

57
58 Search results will be exported into Covidence, merged and checked for duplicates. For the selection of
59 studies two students will be involved, with minimum an undergraduate level of education in a health-related
60

1
2
3 field and previous experience with the systematic review methodology. They will be given the systematic
4 review protocol and 5-hour training on the content of the systematic review and basic knowledge of the
5 procedure. For the selection of studies based on title&abstract screening, eligible studies will be selected by
6 two reviewers until a kappa score of 0.8 is achieved with the remainder being selected by one reviewer. Full
7 text papers will be obtained for all references thought potentially eligible by a single reviewer based on
8 title&abstract; all full text papers will be reviewed by two independent reviewers, with disagreements referred
9 to a third, senior-author reviewer. The PRISMA search flow chart will be used to report the number of studies
10 included and excluded at each step in the process, along with the rationale for the exclusion.
11
12
13
14
15
16
17
18
19
20
21

22 *Data extraction*

23
24 Data extraction will be conducted by one author and checked independently by a second author using a pre-
25 defined data extraction form. Extracted variables will pertain to the following domains: general study
26 information, study characteristics (i.e. year of publication, type of sample ascertainment, sample size),
27 participant characteristics (i.e. age at baseline, age at follow up, number of follow up, interval between
28 baseline and each follow-up, exposure and outcome definition and diagnostic tool, covariates that were
29 adjusted in the analyses). Outcome data will include odds ratio, relative risk, hazard ratio, regression
30 coefficients or correlation coefficients with their respective measurements of error and p-values. Information
31 on the sources of funding for each study will be retrieved. Discrepancies between the two authors will be
32 resolved by discussion with a third, senior-author reviewer. When relevant data are missing, corresponding
33 authors will be contacted to obtain the information.
34
35
36
37
38
39
40
41
42
43
44

45 *Risk of bias assessment*

46
47 Risk of bias of included studies' results will be appraised using the Research Triangle Institute Item Bank
48 (RTI-IB) tool. The RTI-IB is a practical, quality-scoring tool for observational studies with a focus on bias and
49 precision.⁶⁶ It has a high inter-rater reliability (75%) and consists of 29 items tapping 12 domains (1)
50 background, (2) sample definition and selection, (3) interventions/exposure, (4) outcomes, (5) creation of
51 treatment groups, (6) blinding, (7) soundness of information, (8) follow-up, (9) analysis comparability, (10)
52 analysis outcome, (11) interpretation, and (12) presentation and reporting. Possible response categories to
53 each item are 'yes', 'no', 'partially', 'cannot determine', and 'not applicable'. The quality appraisal will be
54 performed by two authors independently with discrepancies being resolved by discussion with a third, senior-
55
56
57
58
59
60

1
2
3 author reviewer. Results will be reported narratively and summarized in a descriptive table. Items will be
4 subdivided into six categories: selection bias/confounding, performance bias, attrition bias, detection bias,
5 reporting bias, and information bias. Items are scored as high, low, or unclear risk of bias. If at least one item
6 in a category is scored as high, the risk of bias within this category is scored as moderate risk. If at least 50%
7 of the items in a category are scored as high, the risk of the category is scored as high. Each study will
8 receive a summary score that corresponds to the highest score obtained in any category.⁶⁶
9
10
11
12
13
14
15

16 *Description of primary studies and data analysis*

17
18 Data will be synthesized by a table reporting study type, participant characteristics, exposure and outcome
19 measures, and a second table on the risk of bias assessment. Studies will be combined based on
20 similarities across relevant characteristics, e.g. type of sample ascertainment, age at baseline, duration of
21 follow-up, exposure and outcome definition and diagnostic tool, and meta-analysis will be performed if ≥ 3
22 studies are available. Heterogeneity of pooled estimates will be measured using the I^2 statistic, which
23 represents the percentage of variation attributable to between-study heterogeneity. I^2 values of 25%, 50%,
24 and 75% will be considered as low, medium, and high heterogeneity, respectively.⁶⁷ For the meta-analysis,
25 the choice between a random-effect or fixed-effect model will be based both on the I^2 statistics and the
26 participant-level characteristics of the combined studies. Results of the meta-analyses will be summarized
27 by a forest plot. Meta-analysis and test of heterogeneity will be performed using STATA 14 (StataCorp.
28 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP). A narrative synthesis will
29 be conducted in place of the meta-analysis, should this latter cannot be performed. To test the robustness of
30 the primary hypothesis against study-level characteristics, e.g. risk-of-bias score, sample size, year of
31 publication, sensitivity analyses will be performed by excluding those studies with the characteristic that can
32 potentially be a source of heterogeneity, e.g. excluding studies with a high risk-of-bias score. Likewise, a
33 sensitivity analysis will be performed by removing studies focusing on medically based sleep disorders, i.e.
34 narcolepsy, breathing-related sleep disorders, central sleep apnea, non-rapid/rapid eye movement sleep
35 disorder, restless legs syndrome, substance/medication-induced sleep disorder, and enuresis nocturna
36 primaria, to prevent the possibility that the pooled estimates could be impacted by factors related to the
37 chronicity of these conditions.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 Subgroup analyses will be performed related to relevant participant-level characteristics, e.g. baseline
57 comorbidity, age at baseline, gender, duration of follow up, exposure and outcome definition and diagnostic
58 tool, by calculating pooled estimates in subgroups of studies, e.g. studies of children versus adolescents
59
60

1
2
3 versus young adults, and/or taking different estimates from the same study related to the subgroups of
4 interest, e.g. male versus female. Subgroups will be defined depending on the amount and type of
5 information retrieved.
6

7
8 To assess sensitivity of the pooled estimate to each included study, we will apply the leave-one-out
9 method, which consists of repeating the analysis removing one study at a time.⁶⁸ Potential publication bias
10 and other source of bias will be further assessed by visual inspection of the symmetry of funnel plots.
11

12
13 Quality of evidence will be rated using the Grading of Recommendations Assessment, Development, and
14 Evaluation (GRADE) guidelines taking into account risk of bias, applying the RTI-IB tool; heterogeneity;
15 directness, evaluating the relevance of the sample, the outcomes and the exposure; precision, examining
16 the 95% confidence interval; and publication bias of the included studies. We will assess inter-rater
17 agreement between investigators for study inclusion, data extraction, and methodological quality
18 assessment using Kappa Cohen's coefficient.
19
20
21
22
23
24
25
26
27

28 Discussion

29
30 This systematic review and meta-analysis will synthesize and quantify the existing evidence on insomnia
31 and/or sleep disturbances predicting depression in children and youth.
32

33
34 Understanding the magnitude of the risk of sleep problems predicting later depression in children and youth
35 will contribute significantly to the development of treatment and secondary prevention strategies of
36 depression.^{5 6 69} Sleep is often impaired in child and youth depression.⁷⁰ Treating sleep problems in
37 childhood can become an adjunctive tool to treat more effectively childhood depression but also to change
38 the risk trajectories of depression, reducing the incidence and severity of depressive episodes later in life.
39

40
41 This study will also potentially inform strategies for primary prevention of depression in healthy children and
42 youth. Sleep patterns physiologically change from birth to early adulthood as a consequence of a number of
43 maturational changes in the brain, and as a result of an adjustment to the social environment.^{71 72} The most
44 evident change concerns the duration of sleep, which decreases from approximately 14 hours at 6 months
45 of age to 8 hours at 16 years of age.^{73 74} Another relevant maturational change concerns the sleep-onset
46 time, which delays up to approximately 2 hours when transitioning to adolescence.⁷⁵ This process is typical
47 of puberty, and it is part of the phase delay of a host of circadian rhythms related to gonadal hormones'
48 changes.⁷⁵ The delay in sleep-onset time, called evening chronotype, manifests at a younger age in
49 females than males, corresponding to the sex difference in the onset of puberty.^{72 75} Evidence shows that
50 over the last century child and youth sleep has consistently reduced beyond normative maturational
51
52
53
54
55
56
57
58
59
60

1
2
3 changes.^{76 77} It has been claimed that this “epidemic” shortage of sleep might be related to the concomitant
4 occurrence of the evening chronotype and earlier morning wake-up time of youth compared to younger
5 children.⁷⁸ Other studies claim that decreased sleep in children and youth may instead be due to the
6 increase of electronic screen media use during late hours.⁷⁹ As a result, an increasing proportion of
7 otherwise healthy children and youth is exposed to insufficient sleep. An open question is whether this
8 newly occurring, sleep-deprived child and youth cohort is at risk of depression. Understanding if the same
9 risk pathway identified in affected or at-risk for depression individuals exists also in typically developing
10 children and youth is essential to understand the size and potential consequences of the secular trend
11 toward insufficient sleep and to eventually plan effective programs of primary prevention to reduce the
12 incidence of depression.
13
14
15
16
17
18
19
20
21
22
23

24 Ethics and dissemination: As this is a protocol for systematic review and meta-analysis of published data,
25 ethics review and approval are not required. The findings will be published in a peer-reviewed journal and
26 disseminated at scientific conferences.
27
28

29 Author contributions: CM, BA, MA and PS conceived the idea, planned and designed the study protocol.
30 CM wrote the first draft. SB provided expertise to the search strategy. WW provided expertise to the data
31 extraction and statistical analysis. JH provided critical insights. All authors have approved and contributed
32 to the final written manuscript. CM guarantor of the review.
33
34
35
36

37 Funding statement: This work was supported by the Cundill Centre for Child and Youth Depression, Centre
38 for Addiction and Mental Health, Toronto, Ontario, Canada. Funder’s roles consist of evaluating and funding
39 the grant application if suitable, monitoring and evaluating research outputs, facilitating the implementation
40 of findings in health care, the interaction between researchers and research users, and the dissemination
41 research findings.
42
43
44
45
46

47 Competing interests statement. None declared.
48

49 Word Count: 4,130 words.
50

51 Patients or the public WERE NOT involved in the design, or conduct, or reporting, or dissemination of our
52 research
53
54
55

56 References 57 58 59 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1. Ghandour RM, Sherman LJ, Vladutiu CJ, et al. Prevalence and Treatment of Depression, Anxiety, and Conduct Problems in US Children. *J Pediatr* 2019;206:256-67 e3. doi: 10.1016/j.jpeds.2018.09.021 [published Online First: 2018/10/17]
2. Avenevoli S, Swendsen J, He JP, et al. Major depression in the national comorbidity survey-adolescent supplement: prevalence, correlates, and treatment. *J Am Acad Child Adolesc Psychiatry* 2015;54(1):37-44 e2. doi: 10.1016/j.jaac.2014.10.010 [published Online First: 2014/12/20]
3. Park RJ, Goodyer IM. Clinical guidelines for depressive disorders in childhood and adolescence. *Eur Child Adolesc Psychiatry* 2000;9(3):147-61. [published Online First: 2000/11/30]
4. Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. *Lancet* 2016;388(10047):881-90. doi: 10.1016/S0140-6736(16)30385-3 [published Online First: 2016/06/13]
5. Eckshtain D, Kuppens S, Ugueto A, et al. Meta-Analysis: 13-Year Follow-up of Psychotherapy Effects on Youth Depression. *J Am Acad Child Adolesc Psychiatry* 2019 doi: 10.1016/j.jaac.2019.04.002 [published Online First: 2019/04/21]
6. Weisz JR, Kuppens S, Ng MY, et al. Are Psychotherapies for Young People Growing Stronger? Tracking Trends Over Time for Youth Anxiety, Depression, Attention-Deficit/Hyperactivity Disorder, and Conduct Problems. *Perspect Psychol Sci* 2019;14(2):216-37. doi: 10.1177/1745691618805436 [published Online First: 2018/12/21]
7. Gapstur SM, Drope JM, Jacobs EJ, et al. A blueprint for the primary prevention of cancer: Targeting established, modifiable risk factors. *CA Cancer J Clin* 2018;68(6):446-70. doi: 10.3322/caac.21496 [published Online First: 2018/10/12]
8. Cairns KE, Yap MB, Pilkington PD, et al. Risk and protective factors for depression that adolescents can modify: a systematic review and meta-analysis of longitudinal studies. *J Affect Disord* 2014;169:61-75. doi: 10.1016/j.jad.2014.08.006 [published Online First: 2014/08/27]
9. Christensen H, Batterham PJ, Gosling JA, et al. Effectiveness of an online insomnia program (SHUTi) for prevention of depressive episodes (the GoodNight Study): a randomised controlled trial. *Lancet Psychiatry* 2016;3(4):333-41. doi: 10.1016/S2215-0366(15)00536-2 [published Online First: 2016/02/02]
10. Freeman D, Sheaves B, Goodwin GM, et al. The effects of improving sleep on mental health (OASIS): a randomised controlled trial with mediation analysis. *Lancet Psychiatry* 2017;4(10):749-58. doi: 10.1016/S2215-0366(17)30328-0 [published Online First: 2017/09/11]

- 1
2
3 11. Ye YY, Zhang YF, Chen J, et al. Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-i)
4 Improves Comorbid Anxiety and Depression-A Meta-Analysis of Randomized Controlled Trials.
5 *PLoS One* 2015;10(11):e0142258. doi: 10.1371/journal.pone.0142258 [published Online First:
6 2015/11/19]
7
8
9
10 12. Werner-Seidler A, Wong Q, Johnston L, et al. Pilot evaluation of the Sleep Ninja: a smartphone
11 application for adolescent insomnia symptoms. *BMJ open* 2019;9(5):e026502. doi:
12 10.1136/bmjopen-2018-026502 [published Online First: 2019/05/28]
13
14
15
16 13. Waloszek JM, Schwartz O, Simmons JG, et al. The SENSE Study (Sleep and Education: learning New
17 Skills Early): a community cognitive-behavioural therapy and mindfulness-based sleep intervention
18 to prevent depression and improve cardiac health in adolescence. *BMC Psychol* 2015;3:39. doi:
19 10.1186/s40359-015-0096-x
20
21
22
23 14. Blake M, Waloszek JM, Schwartz O, et al. The SENSE study: Post intervention effects of a randomized
24 controlled trial of a cognitive-behavioral and mindfulness-based group sleep improvement
25 intervention among at-risk adolescents. *J Consult Clin Psychol* 2016;84(12):1039-51. doi:
26 10.1037/ccp0000142
27
28
29
30 15. Blake M, Schwartz O, Waloszek JM, et al. The SENSE Study: Treatment Mechanisms of a Cognitive
31 Behavioral and Mindfulness-Based Group Sleep Improvement Intervention for At-Risk Adolescents.
32 *Sleep* 2017;40(6) doi: 10.1093/sleep/zsx061
33
34
35
36 16. Kirschbaum-Lesch I, Gest S, Legenbauer T, et al. Feasibility and Efficacy of Bright Light Therapy in
37 Depressed Adolescent Inpatients. *Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie*
38 2018;46(5):423-29. doi: 10.1024/1422-4917/a000603 [published Online First: 2018/07/18]
39
40
41
42 17. de Bruin EJ, Bogels SM, Oort FJ, et al. Improvements of adolescent psychopathology after insomnia
43 treatment: results from a randomized controlled trial over 1 year. *Journal of child psychology and*
44 *psychiatry, and allied disciplines* 2018;59(5):509-22. doi: 10.1111/jcpp.12834 [published Online First:
45 2017/10/21]
46
47
48
49 18. Dewald-Kaufmann JF, Oort FJ, Meijer AM. The effects of sleep extension and sleep hygiene advice on
50 sleep and depressive symptoms in adolescents: a randomized controlled trial. *Journal of child*
51 *psychology and psychiatry, and allied disciplines* 2014;55(3):273-83. doi: 10.1111/jcpp.12157
52 [published Online First: 2013/11/21]
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

19. Fang H, Tu S, Sheng J, et al. Depression in sleep disturbance: A review on a bidirectional relationship, mechanisms and treatment. *J Cell Mol Med* 2019;23(4):2324-32. doi: 10.1111/jcmm.14170 [published Online First: 2019/02/09]
20. Barclay NL, Gehrman PR, Gregory AM, et al. The heritability of insomnia progression during childhood/adolescence: results from a longitudinal twin study. *Sleep* 2015;38(1):109-18. doi: 10.5665/sleep.4334 [published Online First: 2014/10/18]
21. Cole MG, Dendukuri N. Risk factors for depression among elderly community subjects: a systematic review and meta-analysis. *Am J Psychiatry* 2003;160(6):1147-56. doi: 10.1176/appi.ajp.160.6.1147 [published Online First: 2003/06/05]
22. Pigeon WR, Bishop TM, Krueger KM. Insomnia as a Precipitating Factor in New Onset Mental Illness: a Systematic Review of Recent Findings. *Curr Psychiatry Rep* 2017;19(8):44. doi: 10.1007/s11920-017-0802-x [published Online First: 2017/06/16]
23. Bao YP, Han Y, Ma J, et al. Cooccurrence and bidirectional prediction of sleep disturbances and depression in older adults: Meta-analysis and systematic review. *Neurosci Biobehav Rev* 2017;75:257-73. doi: 10.1016/j.neubiorev.2017.01.032 [published Online First: 2017/02/10]
24. Hertenstein E, Feige B, Gmeiner T, et al. Insomnia as a predictor of mental disorders: A systematic review and meta-analysis. *Sleep Med Rev* 2019;43:96-105. doi: 10.1016/j.smrv.2018.10.006 [published Online First: 2018/12/12]
25. Li L, Wu C, Gan Y, et al. Insomnia and the risk of depression: a meta-analysis of prospective cohort studies. *BMC Psychiatry* 2016;16(1):375. doi: 10.1186/s12888-016-1075-3 [published Online First: 2016/11/07]
26. Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. *J Affect Disord* 2011;135(1-3):10-9. doi: 10.1016/j.jad.2011.01.011 [published Online First: 2011/02/09]
27. Roberts RE, Roberts CR, Chen IG. Impact of insomnia on future functioning of adolescents. *J Psychosom Res* 2002;53(1):561-9. [published Online First: 2002/07/20]
28. Roane BM, Taylor DJ. Adolescent insomnia as a risk factor for early adult depression and substance abuse. *Sleep* 2008;31(10):1351-6. [published Online First: 2008/10/16]
29. Johnson EO, Chilcoat HD, Breslau N. Trouble sleeping and anxiety/depression in childhood. *Psychiatry Res* 2000;94(2):93-102. [published Online First: 2000/05/16]

- 1
2
3 30. Alvaro PK, Roberts RM, Harris JK, et al. The direction of the relationship between symptoms of insomnia
4 and psychiatric disorders in adolescents. *J Affect Disord* 2017;207:167-74. doi:
5 10.1016/j.jad.2016.08.032 [published Online First: 2016/10/11]
6
7
8
9 31. Ritter PS, Hofler M, Wittchen HU, et al. Disturbed sleep as risk factor for the subsequent onset of bipolar
10 disorder--Data from a 10-year prospective-longitudinal study among adolescents and young adults. *J*
11 *Psychiatr Res* 2015;68:76-82. doi: 10.1016/j.jpsychires.2015.06.005 [published Online First:
12 2015/08/01]
13
14
15
16 32. Hayley AC, Skogen JC, Sivertsen B, et al. Symptoms of Depression and Difficulty Initiating Sleep from
17 Early Adolescence to Early Adulthood: A Longitudinal Study. *Sleep* 2015;38(10):1599-606. doi:
18 10.5665/sleep.5056 [published Online First: 2015/07/22]
19
20
21
22 33. Armstrong JM, Ruttle PL, Klein MH, et al. Associations of child insomnia, sleep movement, and their
23 persistence with mental health symptoms in childhood and adolescence. *Sleep* 2014;37(5):901-9.
24 doi: 10.5665/sleep.3656 [published Online First: 2014/05/03]
25
26
27
28 34. Armitage R, Hoffmann RF, Emslie GJ, et al. Sleep microarchitecture as a predictor of recurrence in
29 children and adolescents with depression. *Int J Neuropsychopharmacol* 2002;5(3):217-28. doi:
30 10.1017/S1461145702002948 [published Online First: 2002/10/09]
31
32
33
34 35. Gregory AM, O'Connor TG. Sleep problems in childhood: a longitudinal study of developmental change
35 and association with behavioral problems. *J Am Acad Child Adolesc Psychiatry* 2002;41(8):964-71.
36 doi: 10.1097/00004583-200208000-00015 [published Online First: 2002/08/07]
37
38
39
40 36. Fredriksen K, Rhodes J, Reddy R, et al. Sleepless in Chicago: tracking the effects of adolescent sleep
41 loss during the middle school years. *Child Dev* 2004;75(1):84-95. [published Online First:
42 2004/03/16]
43
44
45 37. Gregory AM, Caspi A, Eley TC, et al. Prospective longitudinal associations between persistent sleep
46 problems in childhood and anxiety and depression disorders in adulthood. *J Abnorm Child Psychol*
47 2005;33(2):157-63. [published Online First: 2005/04/21]
48
49
50
51 38. Gregory AM, Van der Ende J, Willis TA, et al. Parent-reported sleep problems during development and
52 self-reported anxiety/depression, attention problems, and aggressive behavior later in life. *Arch*
53 *Pediatr Adolesc Med* 2008;162(4):330-5. doi: 10.1001/archpedi.162.4.330 [published Online First:
54 2008/04/09]
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

39. Gregory AM, Rijdsdijk FV, Lau JY, et al. The direction of longitudinal associations between sleep problems and depression symptoms: a study of twins aged 8 and 10 years. *Sleep* 2009;32(2):189-99. doi: 10.1093/sleep/32.2.189 [published Online First: 2009/02/26]
40. Touchette E, Chollet A, Galera C, et al. Prior sleep problems predict internalising problems later in life. *J Affect Disord* 2012;143(1-3):166-71. doi: 10.1016/j.jad.2012.05.049 [published Online First: 2012/08/04]
41. Greene G, Gregory AM, Fone D, et al. Childhood sleeping difficulties and depression in adulthood: the 1970 British Cohort Study. *J Sleep Res* 2015;24(1):19-23. doi: 10.1111/jsr.12200 [published Online First: 2014/09/03]
42. Wang B, Eastwood PR, Becker A, et al. Concurrent developmental course of sleep problems and emotional/behavioral problems in childhood and adolescence as reflected by the dysregulation profile. *Sleep* 2019;42(3) doi: 10.1093/sleep/zsy243 [published Online First: 2018/12/07]
43. Wang B, Isensee C, Becker A, et al. Developmental Trajectories of Sleep Problems from Childhood to Adolescence Both Predict and Are Predicted by Emotional and Behavioral Problems. *Front Psychol* 2016;7:1874. doi: 10.3389/fpsyg.2016.01874 [published Online First: 2016/12/19]
44. McCracken JT, Poland RE, Lutchmansingh P, et al. Sleep electroencephalographic abnormalities in adolescent depressives: effects of scopolamine. *Biol Psychiatry* 1997;42(7):577-84. doi: 10.1016/S0006-3223(96)00431-3 [published Online First: 1997/10/06]
45. Rao U, McCracken JT, Lutchmansingh P, et al. Electroencephalographic sleep and urinary free cortisol in adolescent depression: a preliminary report of changes from episode to recovery. *Biol Psychiatry* 1997;41(3):369-73. [published Online First: 1997/02/01]
46. Rao U, Dahl RE, Ryan ND, et al. The relationship between longitudinal clinical course and sleep and cortisol changes in adolescent depression. *Biol Psychiatry* 1996;40(6):474-84. doi: 10.1016/0006-3223(95)00481-5 [published Online First: 1996/09/15]
47. Rao U, Dahl RE, Ryan ND, et al. Heterogeneity in EEG sleep findings in adolescent depression: unipolar versus bipolar clinical course. *J Affect Disord* 2002;70(3):273-80. [published Online First: 2002/07/20]
48. Rao U, Poland RE. Electroencephalographic sleep and hypothalamic-pituitary-adrenal changes from episode to recovery in depressed adolescents. *J Child Adolesc Psychopharmacol* 2008;18(6):607-13. doi: 10.1089/cap.2008.034 [published Online First: 2008/12/26]

- 1
2
3 49. Shain BN, Naylor M, Shipley JE, et al. Imipramine effects on sleep in depressed adolescents: a
4 preliminary report. *Biol Psychiatry* 1990;28(5):459-62. [published Online First: 1990/09/01]
5
6
7 50. Goetz RR, Wolk SI, Coplan JD, et al. Premorbid polysomnographic signs in depressed adolescents: a
8 reanalysis of EEG sleep after longitudinal follow-up in adulthood. *Biol Psychiatry* 2001;49(11):930-
9 42. [published Online First: 2001/05/30]
10
11
12 51. Lovato N, Gradisar M. A meta-analysis and model of the relationship between sleep and depression in
13 adolescents: recommendations for future research and clinical practice. *Sleep Med Rev*
14 2014;18(6):521-9. doi: 10.1016/j.smrv.2014.03.006 [published Online First: 2014/05/27]
15
16
17 52. Zisapel N. Paediatric use of melatonin: Letter to the Editor regarding the manuscript "Current role of
18 melatonin in pediatric neurology: Clinical recommendations" by Bruni et al. *Eur J Paediatr Neurol*.
19 2015 Mar;19(2):122-33. *Eur J Paediatr Neurol* 2017;21(2):418-19. doi: 10.1016/j.ejpn.2016.07.013
20
21
22 [published Online First: 2016/08/16]
23
24
25 53. Bruni O, Alonso-Alconada D, Besag F, et al. Current role of melatonin in pediatric neurology: clinical
26 recommendations. *Eur J Paediatr Neurol* 2015;19(2):122-33. doi: 10.1016/j.ejpn.2014.12.007
27
28
29 [published Online First: 2015/01/03]
30
31
32 54. Ma ZR, Shi LJ, Deng MH. Efficacy of cognitive behavioral therapy in children and adolescents with
33 insomnia: a systematic review and meta-analysis. *Braz J Med Biol Res* 2018;51(6):e7070. doi:
34 10.1590/1414-431x20187070 [published Online First: 2018/05/24]
35
36
37 55. Kalak N, Gerber M, Kirov R, et al. Daily morning running for 3 weeks improved sleep and psychological
38 functioning in healthy adolescents compared with controls. *J Adolesc Health* 2012;51(6):615-22. doi:
39 10.1016/j.jadohealth.2012.02.020 [published Online First: 2012/11/24]
40
41
42 56. van Maanen A, Meijer AM, Smits MG, et al. Effects of Melatonin and Bright Light Treatment in Childhood
43 Chronic Sleep Onset Insomnia With Late Melatonin Onset: A Randomized Controlled Study. *Sleep*
44 2017;40(2) doi: 10.1093/sleep/zsw038 [published Online First: 2017/04/02]
45
46
47 57. Meltzer LJ, Johnson C, Crosette J, et al. Prevalence of diagnosed sleep disorders in pediatric primary
48 care practices. *Pediatrics* 2010;125(6):e1410-8. doi: 10.1542/peds.2009-2725 [published Online
49 First: 2010/05/12]
50
51
52 58. Meltzer LJ, Plaufcan MR, Thomas JH, et al. Sleep problems and sleep disorders in pediatric primary
53 care: treatment recommendations, persistence, and health care utilization. *J Clin Sleep Med*
54 2014;10(4):421-6. doi: 10.5664/jcsm.3620 [published Online First: 2014/04/16]
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

59. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1. doi: 10.1186/2046-4053-4-1 [published Online First: 2015/01/03]
60. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000;283(15):2008-12. doi: 10.1001/jama.283.15.2008 [published Online First: 2000/05/02]
61. Bundy DAP, de Silva N, Horton S, et al. Investment in child and adolescent health and development: key messages from Disease Control Priorities, 3rd Edition. *Lancet* 2018;391(10121):687-99. doi: 10.1016/S0140-6736(17)32417-0 [published Online First: 2017/11/21]
62. Lai YC, Huang MC, Chen HC, et al. Familiality and clinical outcomes of sleep disturbances in major depressive and bipolar disorders. *J Psychosom Res* 2014;76(1):61-7. doi: 10.1016/j.jpsychores.2013.10.020 [published Online First: 2013/12/24]
63. Paez A. Gray literature: An important resource in systematic reviews. *J Evid Based Med* 2017;10(3):233-40. doi: 10.1111/jebm.12266 [published Online First: 2017/09/01]
64. McLeod BD, Weisz JR. Using dissertations to examine potential bias in child and adolescent clinical trials. *J Consult Clin Psychol* 2004;72(2):235-51. doi: 10.1037/0022-006X.72.2.235 [published Online First: 2004/04/07]
65. Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts. *Cochrane Database Syst Rev* 2007(2):MR000005. doi: 10.1002/14651858.MR000005.pub3 [published Online First: 2007/04/20]
66. Viswanathan M, Berkman ND. Development of the RTI item bank on risk of bias and precision of observational studies. *J Clin Epidemiol* 2012;65(2):163-78. doi: 10.1016/j.jclinepi.2011.05.008 [published Online First: 2011/10/01]
67. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21(11):1539-58. doi: 10.1002/sim.1186 [published Online First: 2002/07/12]
68. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. *Int J Epidemiol* 2008;37(5):1148-57. doi: 10.1093/ije/dyn065 [published Online First: 2008/04/22]
69. Gregory AM, Sadeh A. Sleep, emotional and behavioral difficulties in children and adolescents. *Sleep Med Rev* 2012;16(2):129-36. doi: 10.1016/j.smrv.2011.03.007 [published Online First: 2011/06/17]

- 1
2
3 70. Rao U, Chen LA. Characteristics, correlates, and outcomes of childhood and adolescent depressive
4 disorders. *Dialogues Clin Neurosci* 2009;11(1):45-62. [published Online First: 2009/05/13]
5
6
7 71. Galland BC, Taylor BJ, Elder DE, et al. Normal sleep patterns in infants and children: a systematic
8 review of observational studies. *Sleep Med Rev* 2012;16(3):213-22. doi: 10.1016/j.smrv.2011.06.001
9 [published Online First: 2011/07/26]
10
11
12 72. Tarokh L, Saletin JM, Carskadon MA. Sleep in adolescence: Physiology, cognition and mental health.
13 *Neurosci Biobehav Rev* 2016;70:182-88. doi: 10.1016/j.neubiorev.2016.08.008 [published Online
14 First: 2016/10/22]
15
16
17 73. Jenni OG, Molinari L, Cafilisch JA, et al. Sleep duration from ages 1 to 10 years: variability and stability in
18 comparison with growth. *Pediatrics* 2007;120(4):e769-76. doi: 10.1542/peds.2006-3300 [published
19 Online First: 2007/10/03]
20
21
22 74. Iglowstein I, Jenni OG, Molinari L, et al. Sleep duration from infancy to adolescence: reference values
23 and generational trends. *Pediatrics* 2003;111(2):302-7. doi: 10.1542/peds.111.2.302 [published
24 Online First: 2003/02/04]
25
26
27 75. Hummer DL, Lee TM. Daily timing of the adolescent sleep phase: Insights from a cross-species
28 comparison. *Neurosci Biobehav Rev* 2016;70:171-81. doi: 10.1016/j.neubiorev.2016.07.023
29 [published Online First: 2016/10/22]
30
31
32 76. Matricciani L, Olds T, Petkov J. In search of lost sleep: secular trends in the sleep time of school-aged
33 children and adolescents. *Sleep Med Rev* 2012;16(3):203-11. doi: 10.1016/j.smrv.2011.03.005
34 [published Online First: 2011/05/27]
35
36
37 77. Keyes KM, Maslowsky J, Hamilton A, et al. The great sleep recession: changes in sleep duration among
38 US adolescents, 1991-2012. *Pediatrics* 2015;135(3):460-8. doi: 10.1542/peds.2014-2707 [published
39 Online First: 2015/02/18]
40
41
42 78. Adolescent Sleep Working G, Committee on A, Council on School H. School start times for adolescents.
43 *Pediatrics* 2014;134(3):642-9. doi: 10.1542/peds.2014-1697 [published Online First: 2014/08/27]
44
45
46 79. Stiglic N, Viner RM. Effects of screentime on the health and well-being of children and adolescents: a
47 systematic review of reviews. *BMJ open* 2019;9(1):e023191. doi: 10.1136/bmjopen-2018-023191
48 [published Online First: 2019/01/05]
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Database: Ovid MEDLINE: Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE® Daily and Ovid MEDLINE® <1946-Present>

Search Strategy:

- 1 exp Sleep Wake Disorders/
- 2 exp Sleep/
- 3 (apnea\$ adj3 sleep\$).mp.
- 4 (restless adj3 leg\$ adj3 syndrome\$).mp.
- 5 narcolep\$.mp.
- 6 (night\$ adj3 terror\$).mp.
- 7 sleep\$.mp.
- 8 dyssomni\$.mp.
- 9 parasomni\$.mp.
- 10 insomni\$.mp.
- 11 exp Depressive Disorder/
- 12 exp Depression/
- 13 depress\$.mp.
- 14 exp Child/
- 15 exp Adolescents/
- 16 exp Young Adult/
- 17 (child\$ or juvenile\$ or pubescen\$ or prepubescen* or pre-pubescen* or teen\$ or preteen\$ or tween\$ or youth\$ or adoles\$ or young\$ adult\$ or emerg\$ adult\$).mp.
- 18 exp Epidemiologic studies/
- 19 exp Case control studies/
- 20 exp Cohort studies/
- 21 case control.tw.
- 22 (cohort adj (study or studies)).tw.
- 23 cohort analy\$.tw.
- 24 (follow up adj (study or studies)).tw.
- 25 (observational adj (study or studies)).tw.
- 26 longitudinal.tw.

1
2
3 27 *retrospective.tw.*
4
5 28 *cross sectional.tw.*
6
7 29 *cross-sectional studies/*
8
9 30 *or/1-10*
10
11 31 *or/11-13*
12
13 32 *or/14-17*
14
15 33 *or/18-29*
16
17 34 *30 and 31 and 32 and 33*
18
19 35 *limit 34 to yr="1980 -Current"*
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

Reporting Item		Page Number
Title		
Identification	#1a Identify the report as a protocol of a systematic review	1
Update	#1b If the protocol is for an update of a previous systematic review, identify as such	n/a
Registration		
	#2 If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors		
Contact	#3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	#3b Describe contributions of protocol authors and identify the guarantor of the review	12
Amendments		

1	#4	If the protocol represents an amendment of a previously completed or	n/a
2		published protocol, identify as such and list changes; otherwise, state	
3		plan for documenting important protocol amendments	
4			
5			
6	Support		
7			
8	Sources	#5a Indicate sources of financial or other support for the review	12
9			
10	Sponsor	#5b Provide name for the review funder and / or sponsor	n/a
11			
12	Role of sponsor or	#5c Describe roles of funder(s), sponsor(s), and / or institution(s), if any,	12
13	funder	in developing the protocol	
14			
15			
16	Introduction		
17			
18	Rationale	#6 Describe the rationale for the review in the context of what is already	3-5
19		known	
20	Objectives	#7 Provide an explicit statement of the question(s) the review will	6
21		address with reference to participants, interventions, comparators, and	
22		outcomes (PICO)	
23			
24			
25			
26			
27			
28	Methods		
29			
30	Eligibility criteria	#8 Specify the study characteristics (such as PICO, study design, setting,	6-7
31		time frame) and report characteristics (such as years considered,	
32		language, publication status) to be used as criteria for eligibility for	
33		the review	
34			
35			
36			
37	Information sources	#9 Describe all intended information sources (such as electronic	8
38		databases, contact with study authors, trial registers or other grey	
39		literature sources) with planned dates of coverage	
40			
41			
42			
43	Search strategy	#10 Present draft of search strategy to be used for at least one electronic	8
44		database, including planned limits, such that it could be repeated	
45			
46			
47	Study records - data	#11a Describe the mechanism(s) that will be used to manage records and	9
48	management	data throughout the review	
49			
50	Study records -	#11b State the process that will be used for selecting studies (such as two	9
51	selection process	independent reviewers) through each phase of the review (that is,	
52		screening, eligibility and inclusion in meta-analysis)	
53			
54			
55			
56	Study records - data	#11c Describe planned method of extracting data from reports (such as	10
57	collection process	piloting forms, done independently, in duplicate), any processes for	
58			
59			
60			

		obtaining and confirming data from investigators	
1			
2			
3	Data items	#12 List and define all variables for which data will be sought (such as	10
4		PICO items, funding sources), any pre-planned data assumptions and	
5		simplifications	
6			
7			
8	Outcomes and	#13 List and define all outcomes for which data will be sought, including	9-10
9	prioritization	prioritization of main and additional outcomes, with rationale	
10			
11			
12	Risk of bias in	#14 Describe anticipated methods for assessing risk of bias of individual	10
13	individual studies	studies, including whether this will be done at the outcome or study	
14		level, or both; state how this information will be used in data synthesis	
15			
16			
17	Data synthesis	#15a Describe criteria under which study data will be quantitatively	10-11
18		synthesised	
19			
20			
21	Data synthesis	#15b If data are appropriate for quantitative synthesis, describe planned	10-11
22		summary measures, methods of handling data and methods of	
23		combining data from studies, including any planned exploration of	
24		consistency (such as I ² , Kendall's τ)	
25			
26			
27			
28	Data synthesis	#15c Describe any proposed additional analyses (such as sensitivity or	10-11
29		subgroup analyses, meta-regression)	
30			
31	Data synthesis	#15d If quantitative synthesis is not appropriate, describe the type of	10-11
32		summary planned	
33			
34			
35	Meta-bias(es)	#16 Specify any planned assessment of meta-bias(es) (such as publication	10-11
36		bias across studies, selective reporting within studies)	
37			
38			
39	Confidence in	#17 Describe how the strength of the body of evidence will be assessed	11
40	cumulative	(such as GRADE)	
41	evidence		
42			
43			

The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. This checklist was completed on 26. September 2019 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Do insomnia and/or sleep disturbances predict the onset, relapse or worsening of depression in community and clinical samples of children and youth? Protocol for a systematic review and meta-analysis.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034606.R2
Article Type:	Protocol
Date Submitted by the Author:	13-Jul-2020
Complete List of Authors:	marino, cecilia; Centre for Addiction and Mental Health, Andrade, Brendan; University of Toronto Department of Psychiatry, Aitken, Madison; Centre for Addiction and Mental Health Bonato, Sarah; Centre for Addiction and Mental Health Centre for Addiction and Mental Health, Library Services Haltigan, John; Centre for Addiction and Mental Health Wang, Wei; Centre for Addiction and Mental Health Szatmari, Peter; Centre for Addiction and Mental Health
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Mental health
Keywords:	SLEEP MEDICINE, Depression & mood disorders < PSYCHIATRY, Child & adolescent psychiatry < PSYCHIATRY, longitudinal studies, systematic review

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 Do insomnia and/or sleep disturbances predict the onset, relapse or worsening of depression in community
4 and clinical samples of children and youth? Protocol for a systematic review and meta-analysis.
5
6
7

8 Cecilia Marino^{1,2}, Brendan Andrade^{1,2}, Madison Aitken,^{1,2} Sarah Bonato¹, John Haltigan^{1,2}, Wei Wang^{1,2} and
9 Peter Szatmari^{1,2,3}
10

11
12 ¹ Cundill Centre for Child and Youth Depression, Center for Addiction and Mental Health, Toronto, Canada

13
14 ² Department of Psychiatry, University of Toronto, Toronto, Canada

15
16 ³ Hospital for Sick Children, Toronto, Ontario, Canada
17

18 Corresponding author: Cecilia Marino, Centre for Addiction and Mental Health (CAMH), 80 Workman Way,
19 Room 1236, Toronto, ON M6J 1H4, e-mail: cecilia.marino@utoronto.ca, Tel: 416-535-8501 Ext. 35134
20

21
22 Brendan Andrade, Brendan.Andrade@camh.ca
23

24 Madison Aitken, Madison.Aitken@camh.ca
25

26 Sarah Bonato, Sarah.Bonato@camh.ca
27

28 John Haltigan, John.Haltigan@camh.ca
29

30 Wei Wang, Wei.Wang@camh.ca
31

32 Peter Szatmari, peter.szatmari@utoronto.ca
33
34
35
36
37
38

39 Abstract

40 Introduction

41
42 Disturbed sleep represents a potentially important modifiable risk factor for the development of depression
43 in children and youth. This protocol for a systematic review proposes to investigate whether insomnia
44 and/or sleep disturbances predict child and youth depression in community and clinical-based samples.
45
46
47
48

49 Methods and analysis

50
51 The protocol adheres to the Preferred Reporting Items for Systematic Review and Meta-Analysis protocols
52 (PRISMA-P) guidelines. English-written, longitudinal studies that quantitatively estimated the prediction of
53 depression by insomnia and/or sleep disturbances in individuals 5-24 years of age will be included.
54
55 EMBASE, MEDLINE, PsychINFO, Scopus and Web of Science and grey literature will be searched from
56 1980 to the present. For the selection of studies, two reviewers will be involved. Data extraction will be
57 conducted by one author and checked independently by a second author. Risk of bias will be appraised
58
59
60

1
2
3 using the Research Triangle Institute Item Bank (RTI-IB) tool. Heterogeneity will be measured using the I^2
4
5 statistic. Meta-analysis will be carried out if ≥ 3 results are available and if outcome measures can be
6
7 pooled. The choice between a random-effect or fixed-effect model will be based both on the I^2 statistics and
8
9 the participant and study characteristics of the combined studies. Results of the meta-analyses will be
10
11 summarized by a forest plot. Analyses will be performed in subgroups stratified by key variables defined
12
13 depending on the amount and type of information retrieved.

14
15 A narrative synthesis will be conducted in place of the meta-analysis, should pooling of data not be
16
17 possible. Quality of evidence will be rated using the Grading of Recommendations Assessment,
18
19 Development, and Evaluation (GRADE) guidelines.

20
21 As this is a protocol for systematic review and meta-analysis of published data, ethics review and approval
22
23 are not required. The findings will be published in a peer-reviewed journal and disseminated at scientific
24
25 conferences and to patient advocacy organizations.

26 27 28 29 30 Strengths and limitations of this study

- 31
32 • This is a protocol for a systematic review and meta-analysis of existing prospective, longitudinal
33
34 evidence on insomnia and/or sleep disturbances predicting depression in children and youth.
 - 35
36 • This protocol will adhere to the Preferred Reporting Items for Systematic review and Meta-Analysis
37
38 protocols (PRISMA-P) guidelines
 - 39
40 • This protocol is registered at PROSPERO, the international prospective register of systematic
41
42 reviews
 - 43
44 • Full-text screening and extraction will be performed by two reviewers. Any uncertainty regarding
45
46 selection will be resolved by consensus and if necessary, by a third reviewer.
 - 47
48 • With regards to limitations, the review will not include treatment studies and will include only
49
50 English-written articles. We include individuals aged 5-24 years, therefore excluding studies on
51
52 child and youth disturbed sleep predicting depression at later stages of life.
- 53
54
55
56
57
58

59 Trial registration number: International Prospective Register for Systematic Reviews (PROSPERO)
60 registration number CRD42019136729.

Introduction

A recent epidemiological study analyzing data from the 2016 National Survey of Children's Health reports prevalence estimates of depression of 1.7% and 6.1% in 6-11 and 12-17 years age-ranges, respectively.¹

The incidence of depression peaks at 20 years of age² with disrupting effects on normative developmental trajectories. Prevalence is equal for both sexes prior to puberty, then it is higher in females.³ Treatment shows limited efficacy,⁴⁻⁶ suggesting that prevention may be a more effective resource to reduce the incidence of depression.

Targeting modifiable risk factors of illnesses is becoming a relevant therapeutic strategy for disease prevention.⁷ Among modifiable risk factors predicting child and youth depression, insomnia is increasingly recognized as an important component of the complex and multi-factorial causal pathway of depression.⁸

Treating insomnia to specifically reduce the incidence and/or severity of depression has been the focus of controlled, high quality, randomized treatment studies in depressed or at risk for depression adult or elderly individuals.⁹⁻¹⁰ In a recent meta-analysis, internet-based cognitive behavioural therapy (CBT) for insomnia had a significant, small effect on comorbid depression in individuals older than 18 years.¹¹

Similar evidence in younger individuals is scarce, mostly consists of studies with small sample size/no follow-up, and it is limited to individuals older than 12 years of age¹²⁻¹⁸.

In a randomized controlled trial, CBT for insomnia for six weekly sessions and a booster session after 2 months was significantly more effective in decreasing comorbid depression compared to waitlist in 12-19-year-old individuals with DSM-5 insomnia and no comorbid psychiatric disorders. The effect was large, was maintained after 12 months, and was fully mediated by the reduction of insomnia symptoms.¹⁷

In a longitudinal, randomised controlled trial study (SENSE, i.e. Sleep and Education: learning New Skills Early) the preventative effect on the incidence of depression in at risk for depression, 12-17-year-old adolescents with sleeping difficulties is investigated.¹³ The interventions consist of seven weekly sessions of either a CBT/mindfulness-based sleep intervention or an active control intervention, followed by two booster sessions after three and six months post-intervention. One-hundred-twenty-three participants have completed the interventions,¹⁴⁻¹⁵ however findings regarding the main outcomes of the study (preventative effects of depression) from the two-year follow-up are not available yet.

It is currently not known whether treating sleep problems in depressed or at risk for depression children (e.g. children with history of abuse, with high emotional dysregulation, offspring of depressed parents)

1
2
3 would lead to a reduction or lower incidence of depression, respectively, than it would be if sleep problems
4 were not treated.¹⁹ To understand whether earlier prevention efforts could be more effective, a precise
5 quantitative estimate of the prediction of depression by insomnia in the entire developmental population,
6 including depressed and non-depressed individuals, is needed.
7
8
9

10
11 Insomnia consists of clinically significant long sleep-onset latency and/or awakening after sleep onset
12 and/or early-morning awakening, accompanied by diurnal tiredness and functional impairment. Prevalence
13 of insomnia is 19.5% in children, equally distributed among boys and girls; in youth, prevalence is 17.4%,
14 and higher among girls.²⁰
15
16
17

18
19 Six systematic reviews have summarized cohort studies on insomnia predicting depression.²¹⁻²⁵ Pooled
20 estimates are consistent across reviews ranging 2.10 (95% CI= 1.86-2.38)²⁶-2.83 (95% CI= 1.55-5.17)²⁴,
21 and across subgroups stratified by the most common confounders, e.g. sex [male: 1.46 (95% CI= 1.13-
22 1.88)²⁵; females: 1.96 (95% CI= 1.05-3.66)²⁵], type of ascertainment [sample drawn from a special
23 population: 2.05 (95% CI= 1.53-2.74)²⁵; sample representative of a community or population: 2.34 (95% CI=
24 1.85-2.96)²⁵], and age [individuals of age \geq 60 years: 1.87 (95% CI= 1.47, 2.37)²⁵-1.92 (95% CI: 1.61-
25 2.30)²³; individuals younger than 60 years of age: 2.50 (95% CI= 1.96, 3.20)²⁵].
26
27
28
29

30
31 However, only three of the six systematic reviews included participants younger than 18 years,^{22 25 26} and a
32 pooled estimate, i.e. odds ratio= 2.0 (95% CI= 1.5-2.7), was provided by only one of the three reviews.²⁶
33
34
35

36
37 This estimate was based on three studies up to 2010 and included 7404 participants, whose age ranged
38 between 6 and 16 years.²⁷⁻²⁹ In all three studies, depression was defined according to DSM IV, and
39 insomnia to DSM-IV-TR criteria. The test for heterogeneity for this group did not show a significant index
40 (Q-value= 0.3; df(Q)=2; p=0.9; and I²=0.0). Li et al.²⁵ updated and used the same selection criteria of
41 Baglioni et al.²⁶ and although fifteen new cohort studies were added, no new studies on children and youth
42 were included. Finally, Pigeon et al.²² summarized studies published from 2014 to 2017; four studies on
43 children and youth were included, of which three supported insomnia predicting depression,³⁰⁻³² and one
44 found no such association.³³ All three systematic reviews of this age group excluded studies which did not
45 control for baseline depression. This led to a greatly reduced number of studies. While the rationale of this
46 choice is clear for studies of risk and prediction, it might not have been the ideal choice, due to the overall
47 paucity of studies in the child and youth age-range compared to other age groups. Including studies that did
48 not control for baseline depression would allow testing of whether there are significant differences in the
49 meta-analytic estimates between studies controlling versus not-controlling for this variable. If no differences
50
51
52
53
54
55
56
57
58
59
60

1
2
3 are found, studies not controlling for baseline depression could contribute to the pooled data with an overall
4 increase of the precision for the estimate of the meta-analytic effects.
5

6
7 There is also some evidence available on whether sleep disturbances other than insomnia predicts child
8 and youth depression.³⁴⁻⁴³ This may include increased/short/disrupted sleep duration with/without diurnal
9 sleepiness, sleepwalking/talking, nightmares, bedwetting, breathing-related sleep disorders, and/or
10 circadian disturbances. Furthermore, sleep disturbances more broadly defined may include challenges
11 either generically defined with regards to duration and consistency over time, measured by self-reported
12 questionnaires, interview or by EEG/actigraph-based measures, and scored by either single-item or
13 cumulative scores. A recent meta-analysis summarized studies testing the association of broadly defined
14 sleep disturbances on depression in 12-20-year-old already clinically depressed participants. In all selected
15 studies,⁴⁴⁻⁵⁰ sleep was defined by EEG-based, objective measures. Estimates of the meta-analytic effects
16 identified that EEG-based longer sleep onset latency, more wake after sleep onset and lower sleep efficiency
17 were significant predictors of depression compared to typical sleep (effect sizes ranging .43-.58).⁵¹
18

19
20 Although findings from this review are of crucial importance for potential secondary prevention programs in
21 depressed youth, it would be useful to have summarized data on the longitudinal association of broadly
22 defined sleep disturbances with depression on the entire developmental population, including non-clinical
23 individuals as well as a broader age range, which would allow to apply findings to primary prevention and/or
24 early intervention programs.
25

26
27 Finally, insomnia and/or sleep disturbances are often associated to comorbid psychiatric and medical
28 conditions.¹⁹ Most previous knowledge synthesis studies have excluded comorbidities, limiting the
29 generalizability and transferability of findings. For this reason, in this systematic review studies focusing on
30 both primary and comorbid insomnia and/or sleep disturbances will be included. To understand the extent
31 to which insomnia and/or sleep disturbances have a distinct risk to depression across comorbid disorders,
32 subgroup analyses will be performed.
33

34
35 Understanding whether insomnia and/or sleep disturbances significantly increase the risk of depression in
36 children and youth could lead to variation in clinical practice and inform policy development. Preventive
37 strategies could include treating sleep problems starting as early as childhood. This is particularly important
38 in light of evidence on the differential effectiveness of a number of treatment for sleep problems (e.g.
39 melatonin,^{52 53} cognitive behavioural therapy,⁵⁴ physical exercise,⁵⁵ and bright light therapy⁵⁶) and the fact
40 that sleep problems in children are under-diagnosed⁵⁷ and rarely treated.⁵⁸
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The purpose of this protocol is to outline methods for a systematic review and meta-analysis of data from
4 prospective, longitudinal studies of children and youth ascertained from clinical or community-based
5 samples investigating the role of insomnia and/or sleep disturbances compared to typical sleep as
6 predictors of depression. “Do children and youth with insomnia and/or sleep disturbance have higher rates
7 of later depression than children and youth without insomnia and/or sleep disturbance”?
8
9
10
11

12 We are interested in testing this relationship in the context of both the absence and presence of baseline
13 depression, i.e. whether insomnia and/or sleep disturbance predict both new and relapse/worsening of
14 depression, respectively.
15
16
17

18 Our study will add to the currently available knowledge synthesis in that:
19

- 20 1. It will provide an updated meta-analytic estimate of the effects of insomnia predicting child and
21 youth depression, adding studies from 2010 onward compared to Baglioni et al.²⁶
22
23
- 24 2. By including studies on 5-24-year-old participants from both clinical and non-clinical populations, it
25 will provide a more comprehensive and updated meta-analytic estimate compared to Lovato and
26 Gradisar⁵¹
27
28
- 29 3. It will include studies on participants with/without baseline depression and whether or not controlling
30 for baseline depression
31
32
- 33 4. It will include studies of both primary and comorbid insomnia and/or sleep disturbances
34

35 As a secondary aim, we will test whether insomnia and/or sleep disturbance predict new onset and/or
36 worsening/relapse of depression, by testing the pooled estimate in two subgroups of studies, respectively,
37 those including participants with baseline depression or where baseline depression has been controlled for,
38 and studies including participants without baseline depression or where baseline depression has not been
39 controlled for.
40
41
42
43
44

45 Finally, we aim to explore the sources of potential heterogeneity and examine the robustness of the primary
46 hypothesis against key confounding variables. Specifically, we will address whether the prediction of child
47 and youth depression by insomnia and/or sleep disturbances significantly differ between studies stratified by
48 key variables, e.g. risk of bias score, type of ascertainment, type of sleep disturbance, measurement of
49 outcome, presence of baseline comorbidity, sample size, age group, gender. Subgroups will be defined
50 depending on the amount and type of information retrieved.
51
52
53
54
55

56 **Methods**
57
58
59
60

1
2
3 For the protocol, we will follow the guidelines outlined in “Preferred Reporting Items for Systematic review
4 and Meta-Analysis protocols (PRISMA-P)”.⁵⁹ For the final report we will follow the guidelines set in “Meta-
5 analysis Of Observational Studies in Epidemiology: a proposal for reporting” (MOOSE).⁶⁰
6
7
8
9

10 Patient and Public Involvement: no patient involved
11
12
13

14 Inclusion criteria
15
16
17

18 *Study types*

19
20 This study will include (1) English-written, (2) prospective, longitudinal observational studies that
21 quantitatively estimated the prediction of depression by insomnia and/or sleep disturbances in children and
22 youth. Only those studies reporting odds ratio, relative risk, hazard ratio, regression coefficients or
23 correlation coefficients with their respective measurements of error and p-values will be selected. Grey
24 literature including relevant dissertations/PhD theses and key conference publications will be included. Case
25 series, case reports, systematic reviews, meta-analyses, as well as experimental, retrospective, cross-
26 sectional, treatment, theoretical and position studies will be excluded.
27
28
29
30
31
32
33
34

35 *Population type*

36
37 Mean age to determine eligibility for inclusion of the study is between 5-24 years. This age range was
38 chosen to cover the whole age range of risk for depression in childhood and youth, and to include the period
39 of peak incidence for depression.^{1 2} In our review, we identify three categories: ‘childhood’ between 5 and 9
40 years of age, ‘adolescence’ between 10 and 19 years of age, and ‘young adulthood’ between 20 and 24
41 years of age.⁶¹ For simplicity, the term ‘youth’ refers to individuals whose age is between 10 and 24 years.
42
43
44
45
46
47 Studies focusing on participants belonging to either community or clinical based samples with any comorbid
48 psychiatric/neurological/medical diagnosis will be included.
49
50
51
52

53 *Exposure*

54
55 Studies will be included if focusing on either one of the following two exposures:

- 56 1. Insomnia, defined as clinically significant difficulty in initiating or maintaining sleep or non-restorative
57 sleep, as based on DSM III and later versions. Although the criterion of daytime impairment is
58 required to define clinically significant insomnia, it has been shown that pooled estimates of
59
60

1
2
3 insomnia predicting depression when this criterion is taken into account²⁴ is of comparable
4 magnitude relative to the ones obtained when this criterion is not considered (Baglioni et al. 2011;
5 Li et al. 2016).²⁶ Therefore, to allow for inclusion of the highest number of studies, daytime
6
7 impairment will be free to vary.
8
9

- 10 2. Sleep disturbances, defined as patterns of quality and sleep duration which deviate from expected
11 age-related norms, i.e. increased/short/fragmented sleep duration with or without daytime
12 fatigue/sleepiness, nightmares/terror attacks, circadian disturbances, and/or night walking/talking.
13 Sleep disturbances can be generically defined with regards to duration and consistency over time,
14 and can be based on subjective and/or EEG/actigraph-based, objective measures. Measures can
15 be based on single or multiple items, or a cumulative score of various items. To increase the
16 generalizability of the results, narcolepsy, breathing-related sleep disorders, central sleep apnea,
17 non-rapid/rapid eye movement sleep disorder, restless legs syndrome, substance/medication-
18 induced sleep disorder, and enuresis nocturna primaria may also be included.
19
20
21
22
23
24
25
26
27

28 Exposures' assessment can be administered by a clinician, a researcher, or based on self-report, parent-
29 report, and/or teacher-report questionnaires.
30
31
32

33 *Outcome*

34 Studies will be included if they focus on either one of the following outcomes: major depressive disorder,
35 depressive disorder not otherwise specified, dysthymic disorder, and/or dimensional constructs of
36 depression, i.e. defined by scores from single- or multiple-item questionnaires, internalizing disorders or
37 anxious depression. Studies focusing on anxiety without a measure of depression will not be included.
38 Studies including participants with bipolar disorders will be excluded given that sleep problems' prevalence
39 differ significantly in bipolar versus unipolar disorders.^{47 62} Outcome is measured by standardized and
40 validated tools administered by a clinician, a researcher, and/or based on self-report, parent-report, and/or
41 teacher-report questionnaires.
42
43
44
45
46
47
48
49
50

51 To be included, both exposure and outcome have to be measured at mean age ≥ 5 years and ≤ 24 and the
52 time between the exposure and outcome is \geq one month. To address the research question on the role of
53 insomnia and/or sleep disturbances as predictor of depression, only studies reporting on the exposure
54 measured at least one month before the outcome will be included. When multiple assessments are
55 conducted on the same cohort, each pair where both exposures and outcomes are measured at mean age \leq
56
57
58
59
60 24 and ≥ 5 years and exposures are measured before the outcome will be considered.

Confounders

Studies will be included regardless of whether they contain estimates adjusted for common confounding factors, such as sex, socio-economic status, demographics, type of comorbidity at baseline. Studies that do not control for common confounding factors will be highlighted for potentially confounded results.

Identification of eligible studies and data extraction

Search strategy

The following databases will be searched: EMBASE, MEDLINE, PsychINFO, Scopus and Web of Science. A draft of the Medline search strategy will be developed using a combination of MeSH and keywords terms relating to sleep disorders, depression/depressive disorder and children/adolescents/young adults with the help of a research librarian. The search will be limited to the years 1980 (to focus on current diagnostic terminology from the DSM III) to the present and will also be limited to observational studies using the search filter developed by the Scottish Intercollegiate Guidelines Network (SIGN). The draft Medline search will also be piloted to ensure the sensitivity and efficacy of the final search strategy and will also be reviewed by all of the participating authors (figure 1). The finalized Medline search will be adapted for each bibliographic database individually.

Grey literature, i.e. dissertations and conference proceeding/papers, will be included in the search in order to mitigate against publication bias.⁶³ Dissertations have been noted as providing a valuable methodology and clinical source of information.⁶⁴ Additionally, searching for relevant conference proceedings/papers is recommended in order to identify recent, but unpublished research.⁶⁵

The grey literature will be screened for relevant material, including use of the search checklist Grey Matters: "A Practical Search Tool for Evidence-Based Medicine" from the Canadian Agency for Drugs and Technologies in Health (CADTH), and by also searching other sources to identify relevant dissertations/PhD theses and conference publications, i.e. Proquest Dissertations and Theses, ProceedingsFirst, PapersFirst, Conference Abstracts from Embase, Google Scholar Search. The references of selected articles will also be hand-searched for eligible studies and all the searches will be re-run just before the final analyses to identify additional relevant studies. Experts in the field will be contacted to locate potentially eligible studies and/or unpublished data.

Selection of studies

1
2
3 Search results will be exported into Covidence, merged and checked for duplicates. For the selection of
4 studies two students will be involved, with minimum an undergraduate level of education in a health-related
5 field and previous experience with the systematic review methodology. They will be given the systematic
6 review protocol and 5-hour training on the content of the systematic review and basic knowledge of the
7 procedure. For the selection of studies based on title&abstract screening, eligible studies will be selected by
8 two reviewers until a kappa score of 0.8 is achieved with the remainder being selected by one reviewer. Full
9 text papers will be obtained for all references thought potentially eligible by a single reviewer based on
10 title&abstract; all full text papers will be reviewed by two independent reviewers, with disagreements referred
11 to a third, senior-author reviewer. The PRISMA search flow chart will be used to report the number of studies
12 included and excluded at each step in the process, along with the rationale for the exclusion.
13
14
15
16
17
18
19
20
21
22
23
24
25

26 *Data extraction*

27
28 Data extraction will be conducted by one author and checked independently by a second author using a pre-
29 defined data extraction form. Extracted variables will pertain to the following domains: general study
30 information, study characteristics (i.e. year of publication, type of sample ascertainment, sample size),
31 participant characteristics (i.e. age at baseline, age at follow up, number of follow up, interval between
32 baseline and each follow-up, exposure and outcome definition and diagnostic tool, covariates that were
33 adjusted in the analyses). Outcome data will include odds ratio, relative risk, hazard ratio, regression
34 coefficients or correlation coefficients with their respective measurements of error and p-values. Information
35 on the sources of funding for each study will be retrieved. Discrepancies between the two authors will be
36 resolved by discussion with a third, senior-author reviewer. When relevant data are missing, corresponding
37 authors will be contacted to obtain the information.
38
39
40
41
42
43
44
45
46
47
48

49 Risk of bias assessment

50
51 Risk of bias of included studies' results will be appraised using the Research Triangle Institute Item Bank
52 (RTI-IB) tool. The RTI-B is a practical, quality-scoring tool for observational studies with a focus on bias and
53 precision.⁶⁶ It has a high inter-rater reliability (75%) and consists of 29 items tapping 12 domains (1)
54 background, (2) sample definition and selection, (3) interventions/exposure, (4) outcomes, (5) creation of
55 treatment groups, (6) blinding, (7) soundness of information, (8) follow-up, (9) analysis comparability, (10)
56 analysis outcome, (11) interpretation, and (12) presentation and reporting. Possible response categories to
57
58
59
60

1
2
3 each item are 'yes', 'no', 'partially', 'cannot determine', and 'not applicable'. The quality appraisal will be
4 performed by two authors independently with discrepancies being resolved by discussion with a third, senior-
5 author reviewer. Results will be reported narratively and summarized in a descriptive table. Items will be
6 subdivided into six categories: selection bias/confounding, performance bias, attrition bias, detection bias,
7 reporting bias, and information bias. Items are scored as high, low, or unclear risk of bias. If at least one item
8 in a category is scored as high, the risk of bias within this category is scored as moderate risk. If at least 50%
9 of the items in a category are scored as high, the risk of the category is scored as high. Each study will
10 receive a summary score that corresponds to the highest score obtained in any category.⁶⁶
11
12
13
14
15
16
17
18
19

20 *Description of primary studies and data analysis*

21
22 Data will be synthesized by a table reporting study type, participant characteristics, exposure and outcome
23 measures, and a second table on the risk of bias assessment. Studies will be combined based on
24 similarities across relevant characteristics, e.g. type of sample ascertainment, age at baseline, duration of
25 follow-up, exposure and outcome definition and diagnostic tool, and meta-analysis will be performed if ≥ 3
26 studies are available. Heterogeneity of pooled estimates will be measured using the I^2 statistic, which
27 represents the percentage of variation attributable to between-study heterogeneity. I^2 values of 25%, 50%,
28 and 75% will be considered as low, medium, and high heterogeneity, respectively.⁶⁷ For the meta-analysis,
29 the choice between a random-effect or fixed-effect model will be based both on the I^2 statistics, and the
30 participant and study characteristics of the combined studies. Results of the meta-analyses will be
31 summarized by a forest plot. Meta-analysis and test of heterogeneity will be performed using STATA 14
32 (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP). A narrative
33 synthesis will be conducted in place of the meta-analysis, should this latter cannot be performed. To test
34 the robustness of the primary hypothesis against study-level characteristics, e.g. risk-of-bias score, sample
35 size, year of publication, duration of follow up, exposure and outcome definition and diagnostic tool,
36 sensitivity analyses will be performed by excluding those studies with the characteristic that can potentially
37 be a source of heterogeneity, e.g. excluding studies with a high risk-of-bias score. Likewise, a sensitivity
38 analysis will be performed by removing studies focusing on medically based sleep disorders, i.e.
39 narcolepsy, breathing-related sleep disorders, central sleep apnea, non-rapid/rapid eye movement sleep
40 disorder, restless legs syndrome, substance/medication-induced sleep disorder, and enuresis nocturna
41 primaria, to prevent the possibility that the pooled estimates could be impacted by factors related to the
42 chronicity of these conditions.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Subgroup analyses will be performed related to relevant participant-level characteristics, e.g. baseline
4 comorbidity, age at baseline, gender, by calculating pooled estimates in subgroups of studies, e.g. studies
5 of children versus adolescents versus young adults, and/or taking different estimates from the same study
6 related to the subgroups of interest, e.g. male versus female. Subgroups will be defined depending on the
7 amount and type of information retrieved.
8
9

10
11
12 To assess sensitivity of the pooled estimate to each included study, we will apply the leave-one-out
13 method, which consists of repeating the analysis removing one study at a time.⁶⁸ Potential publication bias
14 and other source of bias will be further assessed by visual inspection of the symmetry of funnel plots.
15
16

17
18 Quality of evidence will be rated using the Grading of Recommendations Assessment, Development, and
19 Evaluation (GRADE) guidelines taking into account risk of bias, applying the RTI-IB tool; heterogeneity;
20 directness, evaluating the relevance of the sample, the outcomes and the exposure; precision, examining
21 the 95% confidence interval; and publication bias of the included studies. We will assess inter-rater
22 agreement between investigators for study inclusion, data extraction, and methodological quality
23 assessment using Kappa Cohen's coefficient.
24
25
26
27
28
29
30
31

32 Discussion

33 This systematic review and meta-analysis will synthesize and quantify the existing evidence on insomnia
34 and/or sleep disturbances predicting depression in children and youth.
35
36

37 Understanding the magnitude of the risk of sleep problems predicting later depression in children and youth
38 will contribute significantly to the development of treatment and secondary prevention strategies of
39 depression.^{5 6 69} Sleep is often impaired in child and youth depression.⁷⁰ Treating sleep problems in
40 childhood can become an adjunctive tool to treat more effectively childhood depression but also to change
41 the risk trajectories of depression, reducing the incidence and severity of depressive episodes later in life.
42
43
44
45
46

47 This study will also potentially inform strategies for primary prevention of depression in healthy children and
48 youth. Sleep patterns physiologically change from birth to early adulthood as a consequence of a number of
49 maturational changes in the brain, and as a result of an adjustment to the social environment.^{71 72} The most
50 evident change concerns the duration of sleep, which decreases from approximately 14 hours at 6 months
51 of age to 8 hours at 16 years of age.^{73 74} Another relevant maturational change concerns the sleep-onset
52 time, which delays up to approximately 2 hours when transitioning to adolescence.⁷⁵ This process is typical
53 of puberty, and it is part of the phase delay of a host of circadian rhythms related to gonadal hormones'
54 changes.⁷⁵ The delay in sleep-onset time, called evening chronotype, manifests at a younger age in
55
56
57
58
59
60

1
2
3 females than males, corresponding to the sex difference in the onset of puberty.^{72 75} Evidence shows that
4 over the last century child and youth sleep has consistently reduced beyond normative maturational
5 changes.^{76 77} It has been claimed that this “epidemic” shortage of sleep might be related to the concomitant
6 occurrence of the evening chronotype and earlier morning wake-up time of youth compared to younger
7 children.⁷⁸ Other studies claim that decreased sleep in children and youth may instead be due to the
8 increase of electronic screen media use during late hours.⁷⁹ As a result, an increasing proportion of
9 otherwise healthy children and youth is exposed to insufficient sleep. An open question is whether this
10 newly occurring, sleep-deprived child and youth cohort is at risk of depression. Understanding if the same
11 risk pathway identified in affected or at-risk for depression individuals exists also in typically developing
12 children and youth is essential to understand the size and potential consequences of the secular trend
13 toward insufficient sleep and to eventually plan effective programs of primary prevention to reduce the
14 incidence of depression. An open question is whether this
15 newly occurring, sleep-deprived child and youth cohort is at risk of depression. Understanding if the same
16 risk pathway identified in affected or at-risk for depression individuals exists also in typically developing
17 children and youth is essential to understand the size and potential consequences of the secular trend
18 toward insufficient sleep and to eventually plan effective programs of primary prevention to reduce the
19 incidence of depression.

20
21
22
23
24
25
26
27
28 Ethics and dissemination: As this is a protocol for systematic review and meta-analysis of published data,
29 ethics review and approval are not required. The findings will be published in a peer-reviewed journal and
30 disseminated at scientific conferences.

31
32
33 Author contributions: CM, BA, MA and PS conceived the idea, planned and designed the study protocol.
34 CM wrote the first draft. SB provided expertise to the search strategy. WW provided expertise to the data
35 extraction and statistical analysis. JH provided critical insights. All authors have approved and contributed
36 to the final written manuscript. CM guarantor of the review.

37
38
39
40
41 Funding statement: The author(s) acknowledge the support of the Cundill Centre for Child and Youth
42 Depression at the Centre for Addiction and Mental Health (CAMH). The views and opinions expressed in
43 this article are those of the author(s) and do not necessarily reflect those of CAMH. Funder’s roles consist
44 of evaluating and funding the grant application if suitable, monitoring and evaluating research outputs,
45 facilitating the implementation of findings in health care, the interaction between researchers and research
46 users, and the dissemination research findings. Since our project was donor funded, there is no
47 award/grant number.

48
49
50
51 Competing interests statement. None declared.

52
53
54
55 Word Count: 4,130 words.

56
57
58
59
60 Patients or the public WERE NOT involved in the design, or conduct, or reporting, or dissemination of our
research

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 Figure 1: Database: Ovid MEDLINE: Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid
4 MEDLINE® Daily and Ovid MEDLINE® <1946-Present>
5
6
7 Search Strategy
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

1. Ghandour RM, Sherman LJ, Vladutiu CJ, et al. Prevalence and Treatment of Depression, Anxiety, and Conduct Problems in US Children. *J Pediatr* 2019;206:256-67 e3. doi: 10.1016/j.jpeds.2018.09.021 [published Online First: 2018/10/17]
2. Avenevoli S, Swendsen J, He JP, et al. Major depression in the national comorbidity survey-adolescent supplement: prevalence, correlates, and treatment. *J Am Acad Child Adolesc Psychiatry* 2015;54(1):37-44 e2. doi: 10.1016/j.jaac.2014.10.010 [published Online First: 2014/12/20]
3. Park RJ, Goodyer IM. Clinical guidelines for depressive disorders in childhood and adolescence. *Eur Child Adolesc Psychiatry* 2000;9(3):147-61. [published Online First: 2000/11/30]
4. Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. *Lancet* 2016;388(10047):881-90. doi: 10.1016/S0140-6736(16)30385-3 [published Online First: 2016/06/13]
5. Eckshtain D, Kuppens S, Ugueto A, et al. Meta-Analysis: 13-Year Follow-up of Psychotherapy Effects on Youth Depression. *J Am Acad Child Adolesc Psychiatry* 2019 doi: 10.1016/j.jaac.2019.04.002 [published Online First: 2019/04/21]
6. Weisz JR, Kuppens S, Ng MY, et al. Are Psychotherapies for Young People Growing Stronger? Tracking Trends Over Time for Youth Anxiety, Depression, Attention-Deficit/Hyperactivity Disorder, and Conduct Problems. *Perspect Psychol Sci* 2019;14(2):216-37. doi: 10.1177/1745691618805436 [published Online First: 2018/12/21]
7. Gapstur SM, Drope JM, Jacobs EJ, et al. A blueprint for the primary prevention of cancer: Targeting established, modifiable risk factors. *CA Cancer J Clin* 2018;68(6):446-70. doi: 10.3322/caac.21496 [published Online First: 2018/10/12]
8. Cairns KE, Yap MB, Pilkington PD, et al. Risk and protective factors for depression that adolescents can modify: a systematic review and meta-analysis of longitudinal studies. *J Affect Disord* 2014;169:61-75. doi: 10.1016/j.jad.2014.08.006 [published Online First: 2014/08/27]
9. Christensen H, Batterham PJ, Gosling JA, et al. Effectiveness of an online insomnia program (SHUTi) for prevention of depressive episodes (the GoodNight Study): a randomised controlled trial. *Lancet Psychiatry* 2016;3(4):333-41. doi: 10.1016/S2215-0366(15)00536-2 [published Online First: 2016/02/02]

- 1
2
3 10. Freeman D, Sheaves B, Goodwin GM, et al. The effects of improving sleep on mental health (OASIS): a
4
5 randomised controlled trial with mediation analysis. *Lancet Psychiatry* 2017;4(10):749-58. doi:
6
7 10.1016/S2215-0366(17)30328-0 [published Online First: 2017/09/11]
8
- 9 11. Ye YY, Zhang YF, Chen J, et al. Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-i)
10
11 Improves Comorbid Anxiety and Depression-A Meta-Analysis of Randomized Controlled Trials.
12
13 *PLoS One* 2015;10(11):e0142258. doi: 10.1371/journal.pone.0142258 [published Online First:
14
15 2015/11/19]
- 16 12. Werner-Seidler A, Wong Q, Johnston L, et al. Pilot evaluation of the Sleep Ninja: a smartphone
17
18 application for adolescent insomnia symptoms. *BMJ open* 2019;9(5):e026502. doi:
19
20 10.1136/bmjopen-2018-026502 [published Online First: 2019/05/28]
21
- 22 13. Waloszek JM, Schwartz O, Simmons JG, et al. The SENSE Study (Sleep and Education: learning New
23
24 Skills Early): a community cognitive-behavioural therapy and mindfulness-based sleep intervention
25
26 to prevent depression and improve cardiac health in adolescence. *BMC Psychol* 2015;3:39. doi:
27
28 10.1186/s40359-015-0096-x
29
- 30 14. Blake M, Waloszek JM, Schwartz O, et al. The SENSE study: Post intervention effects of a randomized
31
32 controlled trial of a cognitive-behavioral and mindfulness-based group sleep improvement
33
34 intervention among at-risk adolescents. *J Consult Clin Psychol* 2016;84(12):1039-51. doi:
35
36 10.1037/ccp0000142
37
- 38 15. Blake M, Schwartz O, Waloszek JM, et al. The SENSE Study: Treatment Mechanisms of a Cognitive
39
40 Behavioral and Mindfulness-Based Group Sleep Improvement Intervention for At-Risk Adolescents.
41
42 *Sleep* 2017;40(6) doi: 10.1093/sleep/zsx061
43
- 44 16. Kirschbaum-Lesch I, Gest S, Legenbauer T, et al. Feasibility and Efficacy of Bright Light Therapy in
45
46 Depressed Adolescent Inpatients. *Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie*
47
48 2018;46(5):423-29. doi: 10.1024/1422-4917/a000603 [published Online First: 2018/07/18]
49
- 50 17. de Bruin EJ, Bogels SM, Oort FJ, et al. Improvements of adolescent psychopathology after insomnia
51
52 treatment: results from a randomized controlled trial over 1 year. *Journal of child psychology and*
53
54 *psychiatry, and allied disciplines* 2018;59(5):509-22. doi: 10.1111/jcpp.12834 [published Online First:
55
56 2017/10/21]
- 57 18. Dewald-Kaufmann JF, Oort FJ, Meijer AM. The effects of sleep extension and sleep hygiene advice on
58
59 sleep and depressive symptoms in adolescents: a randomized controlled trial. *Journal of child*
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

psychology and psychiatry, and allied disciplines 2014;55(3):273-83. doi: 10.1111/jcpp.12157

[published Online First: 2013/11/21]

19. Fang H, Tu S, Sheng J, et al. Depression in sleep disturbance: A review on a bidirectional relationship,

mechanisms and treatment. *J Cell Mol Med* 2019;23(4):2324-32. doi: 10.1111/jcmm.14170

[published Online First: 2019/02/09]

20. Barclay NL, Gehrman PR, Gregory AM, et al. The heritability of insomnia progression during

childhood/adolescence: results from a longitudinal twin study. *Sleep* 2015;38(1):109-18. doi:

10.5665/sleep.4334 [published Online First: 2014/10/18]

21. Cole MG, Dendukuri N. Risk factors for depression among elderly community subjects: a systematic

review and meta-analysis. *Am J Psychiatry* 2003;160(6):1147-56. doi: 10.1176/appi.ajp.160.6.1147

[published Online First: 2003/06/05]

22. Pigeon WR, Bishop TM, Krueger KM. Insomnia as a Precipitating Factor in New Onset Mental Illness: a

Systematic Review of Recent Findings. *Curr Psychiatry Rep* 2017;19(8):44. doi: 10.1007/s11920-

017-0802-x [published Online First: 2017/06/16]

23. Bao YP, Han Y, Ma J, et al. Cooccurrence and bidirectional prediction of sleep disturbances and

depression in older adults: Meta-analysis and systematic review. *Neurosci Biobehav Rev*

2017;75:257-73. doi: 10.1016/j.neubiorev.2017.01.032 [published Online First: 2017/02/10]

24. Hertenstein E, Feige B, Gmeiner T, et al. Insomnia as a predictor of mental disorders: A systematic

review and meta-analysis. *Sleep Med Rev* 2019;43:96-105. doi: 10.1016/j.smrv.2018.10.006

[published Online First: 2018/12/12]

25. Li L, Wu C, Gan Y, et al. Insomnia and the risk of depression: a meta-analysis of prospective cohort

studies. *BMC Psychiatry* 2016;16(1):375. doi: 10.1186/s12888-016-1075-3 [published Online First:

2016/11/07]

26. Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic

evaluation of longitudinal epidemiological studies. *J Affect Disord* 2011;135(1-3):10-9. doi:

10.1016/j.jad.2011.01.011 [published Online First: 2011/02/09]

27. Roberts RE, Roberts CR, Chen IG. Impact of insomnia on future functioning of adolescents. *J*

Psychosom Res 2002;53(1):561-9. [published Online First: 2002/07/20]

28. Roane BM, Taylor DJ. Adolescent insomnia as a risk factor for early adult depression and substance

abuse. *Sleep* 2008;31(10):1351-6. [published Online First: 2008/10/16]

- 1
2
3 29. Johnson EO, Chilcoat HD, Breslau N. Trouble sleeping and anxiety/depression in childhood. *Psychiatry*
4
5 *Res* 2000;94(2):93-102. [published Online First: 2000/05/16]
6
7 30. Alvaro PK, Roberts RM, Harris JK, et al. The direction of the relationship between symptoms of insomnia
8
9 and psychiatric disorders in adolescents. *J Affect Disord* 2017;207:167-74. doi:
10
11 10.1016/j.jad.2016.08.032 [published Online First: 2016/10/11]
12
13 31. Ritter PS, Hofler M, Wittchen HU, et al. Disturbed sleep as risk factor for the subsequent onset of bipolar
14
15 disorder--Data from a 10-year prospective-longitudinal study among adolescents and young adults. *J*
16
17 *Psychiatr Res* 2015;68:76-82. doi: 10.1016/j.jpsychires.2015.06.005 [published Online First:
18
19 2015/08/01]
20
21 32. Hayley AC, Skogen JC, Sivertsen B, et al. Symptoms of Depression and Difficulty Initiating Sleep from
22
23 Early Adolescence to Early Adulthood: A Longitudinal Study. *Sleep* 2015;38(10):1599-606. doi:
24
25 10.5665/sleep.5056 [published Online First: 2015/07/22]
26
27 33. Armstrong JM, Ruttle PL, Klein MH, et al. Associations of child insomnia, sleep movement, and their
28
29 persistence with mental health symptoms in childhood and adolescence. *Sleep* 2014;37(5):901-9.
30
31 doi: 10.5665/sleep.3656 [published Online First: 2014/05/03]
32
33 34. Armitage R, Hoffmann RF, Emslie GJ, et al. Sleep microarchitecture as a predictor of recurrence in
34
35 children and adolescents with depression. *Int J Neuropsychopharmacol* 2002;5(3):217-28. doi:
36
37 10.1017/S1461145702002948 [published Online First: 2002/10/09]
38
39 35. Gregory AM, O'Connor TG. Sleep problems in childhood: a longitudinal study of developmental change
40
41 and association with behavioral problems. *J Am Acad Child Adolesc Psychiatry* 2002;41(8):964-71.
42
43 doi: 10.1097/00004583-200208000-00015 [published Online First: 2002/08/07]
44
45 36. Fredriksen K, Rhodes J, Reddy R, et al. Sleepless in Chicago: tracking the effects of adolescent sleep
46
47 loss during the middle school years. *Child Dev* 2004;75(1):84-95. [published Online First:
48
49 2004/03/16]
50
51 37. Gregory AM, Caspi A, Eley TC, et al. Prospective longitudinal associations between persistent sleep
52
53 problems in childhood and anxiety and depression disorders in adulthood. *J Abnorm Child Psychol*
54
55 2005;33(2):157-63. [published Online First: 2005/04/21]
56
57 38. Gregory AM, Van der Ende J, Willis TA, et al. Parent-reported sleep problems during development and
58
59 self-reported anxiety/depression, attention problems, and aggressive behavior later in life. *Arch*
60
Pediatr Adolesc Med 2008;162(4):330-5. doi: 10.1001/archpedi.162.4.330 [published Online First:
2008/04/09]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

39. Gregory AM, Rijdsdijk FV, Lau JY, et al. The direction of longitudinal associations between sleep problems and depression symptoms: a study of twins aged 8 and 10 years. *Sleep* 2009;32(2):189-99. doi: 10.1093/sleep/32.2.189 [published Online First: 2009/02/26]
40. Touchette E, Chollet A, Galera C, et al. Prior sleep problems predict internalising problems later in life. *J Affect Disord* 2012;143(1-3):166-71. doi: 10.1016/j.jad.2012.05.049 [published Online First: 2012/08/04]
41. Greene G, Gregory AM, Fone D, et al. Childhood sleeping difficulties and depression in adulthood: the 1970 British Cohort Study. *J Sleep Res* 2015;24(1):19-23. doi: 10.1111/jsr.12200 [published Online First: 2014/09/03]
42. Wang B, Eastwood PR, Becker A, et al. Concurrent developmental course of sleep problems and emotional/behavioral problems in childhood and adolescence as reflected by the dysregulation profile. *Sleep* 2019;42(3) doi: 10.1093/sleep/zsy243 [published Online First: 2018/12/07]
43. Wang B, Isensee C, Becker A, et al. Developmental Trajectories of Sleep Problems from Childhood to Adolescence Both Predict and Are Predicted by Emotional and Behavioral Problems. *Front Psychol* 2016;7:1874. doi: 10.3389/fpsyg.2016.01874 [published Online First: 2016/12/19]
44. McCracken JT, Poland RE, Lutchmansingh P, et al. Sleep electroencephalographic abnormalities in adolescent depressives: effects of scopolamine. *Biol Psychiatry* 1997;42(7):577-84. doi: 10.1016/S0006-3223(96)00431-3 [published Online First: 1997/10/06]
45. Rao U, McCracken JT, Lutchmansingh P, et al. Electroencephalographic sleep and urinary free cortisol in adolescent depression: a preliminary report of changes from episode to recovery. *Biol Psychiatry* 1997;41(3):369-73. [published Online First: 1997/02/01]
46. Rao U, Dahl RE, Ryan ND, et al. The relationship between longitudinal clinical course and sleep and cortisol changes in adolescent depression. *Biol Psychiatry* 1996;40(6):474-84. doi: 10.1016/0006-3223(95)00481-5 [published Online First: 1996/09/15]
47. Rao U, Dahl RE, Ryan ND, et al. Heterogeneity in EEG sleep findings in adolescent depression: unipolar versus bipolar clinical course. *J Affect Disord* 2002;70(3):273-80. [published Online First: 2002/07/20]
48. Rao U, Poland RE. Electroencephalographic sleep and hypothalamic-pituitary-adrenal changes from episode to recovery in depressed adolescents. *J Child Adolesc Psychopharmacol* 2008;18(6):607-13. doi: 10.1089/cap.2008.034 [published Online First: 2008/12/26]

- 1
2
3 49. Shain BN, Naylor M, Shipley JE, et al. Imipramine effects on sleep in depressed adolescents: a
4 preliminary report. *Biol Psychiatry* 1990;28(5):459-62. [published Online First: 1990/09/01]
5
6
7 50. Goetz RR, Wolk SI, Coplan JD, et al. Premorbid polysomnographic signs in depressed adolescents: a
8 reanalysis of EEG sleep after longitudinal follow-up in adulthood. *Biol Psychiatry* 2001;49(11):930-
9 42. [published Online First: 2001/05/30]
10
11
12 51. Lovato N, Gradisar M. A meta-analysis and model of the relationship between sleep and depression in
13 adolescents: recommendations for future research and clinical practice. *Sleep Med Rev*
14 2014;18(6):521-9. doi: 10.1016/j.smrv.2014.03.006 [published Online First: 2014/05/27]
15
16
17 52. Zisapel N. Paediatric use of melatonin: Letter to the Editor regarding the manuscript "Current role of
18 melatonin in pediatric neurology: Clinical recommendations" by Bruni et al. *Eur J Paediatr Neurol*.
19 2015 Mar;19(2):122-33. *Eur J Paediatr Neurol* 2017;21(2):418-19. doi: 10.1016/j.ejpn.2016.07.013
20
21
22 [published Online First: 2016/08/16]
23
24
25 53. Bruni O, Alonso-Alconada D, Besag F, et al. Current role of melatonin in pediatric neurology: clinical
26 recommendations. *Eur J Paediatr Neurol* 2015;19(2):122-33. doi: 10.1016/j.ejpn.2014.12.007
27
28
29 [published Online First: 2015/01/03]
30
31
32 54. Ma ZR, Shi LJ, Deng MH. Efficacy of cognitive behavioral therapy in children and adolescents with
33 insomnia: a systematic review and meta-analysis. *Braz J Med Biol Res* 2018;51(6):e7070. doi:
34 10.1590/1414-431x20187070 [published Online First: 2018/05/24]
35
36
37 55. Kalak N, Gerber M, Kirov R, et al. Daily morning running for 3 weeks improved sleep and psychological
38 functioning in healthy adolescents compared with controls. *J Adolesc Health* 2012;51(6):615-22. doi:
39 10.1016/j.jadohealth.2012.02.020 [published Online First: 2012/11/24]
40
41
42 56. van Maanen A, Meijer AM, Smits MG, et al. Effects of Melatonin and Bright Light Treatment in Childhood
43 Chronic Sleep Onset Insomnia With Late Melatonin Onset: A Randomized Controlled Study. *Sleep*
44 2017;40(2) doi: 10.1093/sleep/zsw038 [published Online First: 2017/04/02]
45
46
47 57. Meltzer LJ, Johnson C, Crosette J, et al. Prevalence of diagnosed sleep disorders in pediatric primary
48 care practices. *Pediatrics* 2010;125(6):e1410-8. doi: 10.1542/peds.2009-2725 [published Online
49 First: 2010/05/12]
50
51
52 58. Meltzer LJ, Plaufcan MR, Thomas JH, et al. Sleep problems and sleep disorders in pediatric primary
53 care: treatment recommendations, persistence, and health care utilization. *J Clin Sleep Med*
54 2014;10(4):421-6. doi: 10.5664/jcsm.3620 [published Online First: 2014/04/16]
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

59. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1. doi: 10.1186/2046-4053-4-1 [published Online First: 2015/01/03]
60. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000;283(15):2008-12. doi: 10.1001/jama.283.15.2008 [published Online First: 2000/05/02]
61. Bundy DAP, de Silva N, Horton S, et al. Investment in child and adolescent health and development: key messages from Disease Control Priorities, 3rd Edition. *Lancet* 2018;391(10121):687-99. doi: 10.1016/S0140-6736(17)32417-0 [published Online First: 2017/11/21]
62. Lai YC, Huang MC, Chen HC, et al. Familiarity and clinical outcomes of sleep disturbances in major depressive and bipolar disorders. *J Psychosom Res* 2014;76(1):61-7. doi: 10.1016/j.jpsychores.2013.10.020 [published Online First: 2013/12/24]
63. Paez A. Gray literature: An important resource in systematic reviews. *J Evid Based Med* 2017;10(3):233-40. doi: 10.1111/jebm.12266 [published Online First: 2017/09/01]
64. McLeod BD, Weisz JR. Using dissertations to examine potential bias in child and adolescent clinical trials. *J Consult Clin Psychol* 2004;72(2):235-51. doi: 10.1037/0022-006X.72.2.235 [published Online First: 2004/04/07]
65. Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts. *Cochrane Database Syst Rev* 2007(2):MR000005. doi: 10.1002/14651858.MR000005.pub3 [published Online First: 2007/04/20]
66. Viswanathan M, Berkman ND. Development of the RTI item bank on risk of bias and precision of observational studies. *J Clin Epidemiol* 2012;65(2):163-78. doi: 10.1016/j.jclinepi.2011.05.008 [published Online First: 2011/10/01]
67. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21(11):1539-58. doi: 10.1002/sim.1186 [published Online First: 2002/07/12]
68. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. *Int J Epidemiol* 2008;37(5):1148-57. doi: 10.1093/ije/dyn065 [published Online First: 2008/04/22]
69. Gregory AM, Sadeh A. Sleep, emotional and behavioral difficulties in children and adolescents. *Sleep Med Rev* 2012;16(2):129-36. doi: 10.1016/j.smrv.2011.03.007 [published Online First: 2011/06/17]

- 1
2
3 70. Rao U, Chen LA. Characteristics, correlates, and outcomes of childhood and adolescent depressive
4 disorders. *Dialogues Clin Neurosci* 2009;11(1):45-62. [published Online First: 2009/05/13]
5
6
7 71. Galland BC, Taylor BJ, Elder DE, et al. Normal sleep patterns in infants and children: a systematic
8 review of observational studies. *Sleep Med Rev* 2012;16(3):213-22. doi: 10.1016/j.smrv.2011.06.001
9 [published Online First: 2011/07/26]
10
11
12 72. Tarokh L, Saletin JM, Carskadon MA. Sleep in adolescence: Physiology, cognition and mental health.
13 *Neurosci Biobehav Rev* 2016;70:182-88. doi: 10.1016/j.neubiorev.2016.08.008 [published Online
14 First: 2016/10/22]
15
16
17 73. Jenni OG, Molinari L, Cafilisch JA, et al. Sleep duration from ages 1 to 10 years: variability and stability in
18 comparison with growth. *Pediatrics* 2007;120(4):e769-76. doi: 10.1542/peds.2006-3300 [published
19 Online First: 2007/10/03]
20
21
22 74. Iglowstein I, Jenni OG, Molinari L, et al. Sleep duration from infancy to adolescence: reference values
23 and generational trends. *Pediatrics* 2003;111(2):302-7. doi: 10.1542/peds.111.2.302 [published
24 Online First: 2003/02/04]
25
26
27 75. Hummer DL, Lee TM. Daily timing of the adolescent sleep phase: Insights from a cross-species
28 comparison. *Neurosci Biobehav Rev* 2016;70:171-81. doi: 10.1016/j.neubiorev.2016.07.023
29 [published Online First: 2016/10/22]
30
31
32 76. Matricciani L, Olds T, Petkov J. In search of lost sleep: secular trends in the sleep time of school-aged
33 children and adolescents. *Sleep Med Rev* 2012;16(3):203-11. doi: 10.1016/j.smrv.2011.03.005
34 [published Online First: 2011/05/27]
35
36
37 77. Keyes KM, Maslowsky J, Hamilton A, et al. The great sleep recession: changes in sleep duration among
38 US adolescents, 1991-2012. *Pediatrics* 2015;135(3):460-8. doi: 10.1542/peds.2014-2707 [published
39 Online First: 2015/02/18]
40
41
42 78. Adolescent Sleep Working G, Committee on A, Council on School H. School start times for adolescents.
43 *Pediatrics* 2014;134(3):642-9. doi: 10.1542/peds.2014-1697 [published Online First: 2014/08/27]
44
45
46 79. Stiglic N, Viner RM. Effects of screentime on the health and well-being of children and adolescents: a
47 systematic review of reviews. *BMJ open* 2019;9(1):e023191. doi: 10.1136/bmjopen-2018-023191
48 [published Online First: 2019/01/05]
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 1 exp Sleep Wake Disorders/
4 2 exp Sleep/
5 3 (apnea\$ adj3 sleep\$).mp.
6 4 (restless adj3 leg\$ adj3 syndrome\$).mp.
7 5 narcolep\$.mp.
8 6 (night\$ adj3 terror\$).mp.
9 7 sleep\$.mp.
10 8 dyssomni\$.mp.
11 9 parasomni\$.mp.
12 10 insomni\$.mp.
13 11 exp Depressive Disorder/
14 12 exp Depression/
15 13 depress\$.mp.
16 14 exp Child/
17 15 exp Adolescents/
18 16 exp Young Adult/
19 17 (child\$ or juvenile\$ or pubescen\$ or prepubescen* or pre-pubescen* or teen\$ or preteen\$ or tween\$
20 or youth\$ or adoles\$ or young\$ adult\$ or emerg\$ adult\$).mp.
21 18 exp Epidemiologic studies/
22 19 exp Case control studies/
23 20 exp Cohort studies/
24 21 case control.tw.
25 22 (cohort adj (study or studies)).tw.
26 23 cohort analy\$.tw.
27 24 (follow up adj (study or studies)).tw.
28 25 (observational adj (study or studies)).tw.
29 26 longitudinal.tw.
30 27 retrospective.tw.
31 28 cross sectional.tw.
32 29 cross-sectional studies/
33 30 or/1-10
34 31 or/11-13
35 32 or/14-17
36 33 or/18-29
37 34 30 and 31 and 32 and 33
38 35 limit 34 to yr="1980 -Current"

Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4(1):1.

Reporting Item		Page Number
Title		
Identification	#1a Identify the report as a protocol of a systematic review	1
Update	#1b If the protocol is for an update of a previous systematic review, identify as such	n/a
Registration		
	#2 If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors		
Contact	#3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	#3b Describe contributions of protocol authors and identify the guarantor of the review	12

Amendments

1		#4	If the protocol represents an amendment of a previously completed or	n/a
2			published protocol, identify as such and list changes; otherwise, state	
3			plan for documenting important protocol amendments	
4				
5				
6	Support			
7				
8	Sources	#5a	Indicate sources of financial or other support for the review	12
9				
10	Sponsor	#5b	Provide name for the review funder and / or sponsor	n/a
11				
12	Role of sponsor or	#5c	Describe roles of funder(s), sponsor(s), and / or institution(s), if any,	12
13	funder		in developing the protocol	
14				
15				
16				
17	Introduction			
18				
19	Rationale	#6	Describe the rationale for the review in the context of what is already	3-5
20			known	
21				
22	Objectives	#7	Provide an explicit statement of the question(s) the review will	6
23			address with reference to participants, interventions, comparators, and	
24			outcomes (PICO)	
25				
26				
27				
28	Methods			
29				
30	Eligibility criteria	#8	Specify the study characteristics (such as PICO, study design, setting,	6-7
31			time frame) and report characteristics (such as years considered,	
32			language, publication status) to be used as criteria for eligibility for	
33			the review	
34				
35	Information sources	#9	Describe all intended information sources (such as electronic	8
36			databases, contact with study authors, trial registers or other grey	
37			literature sources) with planned dates of coverage	
38				
39	Search strategy	#10	Present draft of search strategy to be used for at least one electronic	8
40			database, including planned limits, such that it could be repeated	
41				
42	Study records - data	#11a	Describe the mechanism(s) that will be used to manage records and	9
43	management		data throughout the review	
44				
45	Study records -	#11b	State the process that will be used for selecting studies (such as two	9
46	selection process		independent reviewers) through each phase of the review (that is,	
47			screening, eligibility and inclusion in meta-analysis)	
48				
49	Study records - data	#11c	Describe planned method of extracting data from reports (such as	10
50	collection process		piloting forms, done independently, in duplicate), any processes for	
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

		obtaining and confirming data from investigators	
1			
2			
3	Data items	#12 List and define all variables for which data will be sought (such as	10
4		PICO items, funding sources), any pre-planned data assumptions and	
5		simplifications	
6			
7			
8	Outcomes and	#13 List and define all outcomes for which data will be sought, including	9-10
9	prioritization	prioritization of main and additional outcomes, with rationale	
10			
11	Risk of bias in	#14 Describe anticipated methods for assessing risk of bias of individual	10
12	individual studies	studies, including whether this will be done at the outcome or study	
13		level, or both; state how this information will be used in data synthesis	
14			
15			
16			
17	Data synthesis	#15a Describe criteria under which study data will be quantitatively	10-11
18		synthesised	
19			
20			
21	Data synthesis	#15b If data are appropriate for quantitative synthesis, describe planned	10-11
22		summary measures, methods of handling data and methods of	
23		combining data from studies, including any planned exploration of	
24		consistency (such as I ² , Kendall's τ)	
25			
26			
27	Data synthesis	#15c Describe any proposed additional analyses (such as sensitivity or	10-11
28		subgroup analyses, meta-regression)	
29			
30			
31	Data synthesis	#15d If quantitative synthesis is not appropriate, describe the type of	10-11
32		summary planned	
33			
34			
35	Meta-bias(es)	#16 Specify any planned assessment of meta-bias(es) (such as publication	10-11
36		bias across studies, selective reporting within studies)	
37			
38			
39	Confidence in	#17 Describe how the strength of the body of evidence will be assessed	11
40	cumulative	(such as GRADE)	
41	evidence		
42			
43			

The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. This checklist was completed on 26. September 2019 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)